Original Article
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children
N Engl J Med 1997; 336:1855-1859June 26, 1997
- Abstract
Background
A nationwide hepatitis B vaccination program was implemented in Taiwan in July 1984. To assess the effect of the program on the development of hepatocellular carcinoma, we studied the incidence of this cancer in children in Taiwan from 1981 to 1994.
Methods
We collected data on liver cancer in children from Taiwan's National Cancer Registry, which receives reports from each of the country's 142 hospitals with more than 50 beds. Data on childhood liver cancer were also obtained from Taiwan's 17 major medical centers. To prevent the inclusion of cases of hepatoblastoma, the primary analysis was confined to liver cancers in children six years of age or older. Data were also obtained on mortality from liver cancer among children.
Results
The average annual incidence of hepatocellular carcinoma in children 6 to 14 years of age declined from 0.70 per 100,000 children between 1981 and 1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P<0.01). The corresponding rates of mortality from hepatocellular carcinoma also decreased. The incidence of hepatocellular carcinoma in children 6 to 9 years of age declined from 0.52 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001).
Conclusions
Since the institution of Taiwan's program of universal hepatitis B vaccination, the incidence of hepatocellular carcinoma in children has declined.
Media in This Article
Figure 1
Comparison of the Incidence of Liver Cancer in Children 6 to 14 and 0 to 5 Years of Age, According to Birth Cohort.Table 1
Estimated Hepatitis B Vaccine and Hepatitis B Immune Globulin (HBIG) Coverage Rates in Infants and Hepatitis B Vaccine Coverage Rate and HBsAg Seroprevalence in Six-Year-Olds.Article Activity
- Article
Hepatocellular carcinoma is closely associated with hepatitis virus infections, particularly infection with hepatitis B virus (HBV).1-6 However, the cause-and-effect relation of HBV to hepatocellular carcinoma is as yet unproved. In Taiwan the association between hepatocellular carcinoma and HBV is stronger in children than in adults. The rate of seropositivity for hepatitis B surface antigen (HBsAg) approaches 100 percent in children with hepatocellular carcinoma,7,8 as compared with 70 to 80 percent in adults with the disease. Integration of the HBV genome into the host genome of hepatocellular carcinoma has been reported in children.9
To control hepatitis B, Taiwan launched a nationwide vaccination program in 1984.10,11 In 10 years, this program reduced the HBsAg carrier rate in children from 10 percent to less than 1 percent.12 However, it remains unclear whether the ultimate goal of reducing HBV-induced mortality, particularly that from hepatocellular carcinoma, can be achieved. Since the incidence of hepatocellular carcinoma in Taiwan peaks in the sixth decade of life,6 it may take 40 years or longer to see an overall decrease in the rate of hepatocellular carcinoma as a result of the vaccination program. The rate of hepatocellular carcinoma in children can be considered as an early indicator of the effectiveness of vaccination in reducing the rate of hepatocellular carcinoma. A decrease in the rate in children after universal vaccination against hepatitis B would provide further evidence that HBV is a cause of hepatocellular carcinoma.
Methods
Population Data
In Taiwan, which has a population of 21 million, the health care system changed little from 1981 to 1994. All births, deaths, marriages, and divorces must be registered with the government's household-registration offices. Information on education, employment, and migration is also recorded. These records are double-checked annually by registration officers, who conduct home visits. Demographic data obtained from household-registration offices are complete and accurate. The year-end population statistics for children used in this study were obtained from the annual reports on demographic statistics published by the Ministry of Interior.
Nationwide Hepatitis B Vaccination Program
Taiwan's mass-vaccination program against hepatitis B was launched in July 1984.10,11 For the first two years, the program covered only neonates born to mothers who were HBsAg carriers, but it was extended to all neonates in July 1986, to preschool children in July 1987, to primary-school children in 1988, to middle-school children in 1989, and to adults in 1990. Infants were given 5-μg doses of a plasma-derived HBV vaccine (Hevac B, Institut Pasteur, Marnes-la-Coquette, France) at birth and at 1, 2, and 12 months of age. In addition, 0.5 ml (145 IU) of hepatitis B immune globulin (Abbott Laboratories, Cutter, or Green Cross, Taiwan) was given within 24 hours after birth to infants whose mothers had hepatitis B e antigen (HBeAg) or reciprocal serum titers of HBsAg higher than 2560. Since November 1992, recombinant HBV vaccines have replaced plasma-derived vaccines and have been given at birth and at one and six months of age. The government has covered all the costs of the program. Those who miss the scheduled vaccination are encouraged to receive hepatitis B vaccines on a fee-for-service basis. In addition, HBV vaccine paid for by parents was given to preschool children from 1987 to 1994. The estimated vaccine coverage from 1981 to 1994 in infancy and at six years of age is shown in Table 1Table 1
Estimated Hepatitis B Vaccine and Hepatitis B Immune Globulin (HBIG) Coverage Rates in Infants and Hepatitis B Vaccine Coverage Rate and HBsAg Seroprevalence in Six-Year-Olds..Inclusion Criteria for Cases of Childhood Hepatocellular Carcinoma
All cases of liver cancer among children 6 to 14 years of age in Taiwan between 1981 and 1994 were included in our study except those that were a type other than hepatocellular carcinoma. Children younger than six years old were also excluded to prevent the inclusion of cases of hepatoblastoma.13,14
Trends in the Annual Incidence of Childhood Hepatocellular Carcinoma
To look for trends in the incidence of childhood hepatocellular carcinoma after the program was implemented, we used three systems to study the incidence of this disease from July 1981 to June 1994. July 1 was used as a starting point for each year because the vaccination program was launched on July 1, 1984.
System 1: National Cancer Registry
We analyzed information, obtained from the data bank of the Taiwan National Cancer Registry of the Department of Health, on cases that occurred between July 1981 and June 1994 in children under 14 years of age. This registry was established in 1979. Cases of cancer at each of Taiwan's 142 hospitals with more than 50 beds were reported. We used data from 1981 onward to avoid possible gaps in reporting of data at the beginning of this system. The items registered included the patient's name, national identification number, date of birth, sex, date of diagnosis, location of tumor, and histologic data.
System 2: Multicenter Childhood Hepatocellular Carcinoma Registration Study
To ensure the accuracy of the data from the National Cancer Registry, we simultaneously conducted a multicenter collaborative study of the registry of childhood hepatocellular carcinoma. Pediatric gastroenterologists or oncologists from 17 major hospitals, including all 10 tertiary referral centers in Taiwan, participated in this study. In addition to the data in the National Cancer Registry, this study included information on serum concentrations of HBsAg, alpha-fetoprotein levels, and history of vaccination against hepatitis B.
The data collected from these two systems were then merged, and the cases that did not overlap were added together after each was confirmed by the reporting hospital. According to the capture–recapture method,15 the total number of children with hepatocellular carcinoma during the study period is estimated to be 294 (95 percent confidence interval, 272 to 316). The cases identified by systems 1 and 2 are estimated to be 84 percent of all cases of childhood hepatocellular carcinoma. The rate was not affected by age.
System 3: National Mortality Registry
Data on deaths in Taiwan between 1969 and 1993 among children under 15 years of age were also analyzed for trends in mortality resulting from childhood hepatocellular carcinoma during the study period.
Death certificates, which must be registered with the household-registration offices, are routinely reviewed and submitted to the national death-certification system by local health centers. By law, a certificate must be registered within one month of a death. All certificates are reviewed and coded by medical registrars according to the Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death 16 in the central office of the national death-certification system. The diagnosis and classification of underlying causes of death in Taiwan vary from area to area according to the level of medical services. In some cases, primary liver cancer may not be listed as the underlying cause for children who in fact died from the disease, since other diagnostic terms may sometimes be used to describe the immediate cause of death. On the other hand, some metastatic liver tumors may be misclassified as primary liver cancer. Therefore, the mortality data were not merged with the more reliable incidence data.
Incidence of Brain Tumors as a Control Variable
The incidence of brain tumors, common malignant tumors in children 6 to 14 years of age, was used as a control variable. The diagnosis is usually not difficult, and there was no reason to expect any change in incidence during the study period.
Correlation between History of HBV Vaccination and Childhood Hepatocellular Carcinoma
The history of vaccination against hepatitis B, including the date of administration of each dose of hepatitis B vaccine and hepatitis B immune globulin, has been registered at the national level for each neonate in the program since July 1984, the beginning of the nationwide vaccination program.10 This record was retrieved and reviewed for each child with hepatocellular carcinoma born after July 1984.
Statistical Analysis
The annual incidence of childhood hepatocellular carcinoma was determined by dividing the annual number of cases in children 6 to 14 years of age by the year-end population of children of the same age. The statistical significance of the difference in the incidence of childhood hepatocellular carcinoma for the two periods under comparison was examined by using the Poisson test.17
In order to compare the incidence rates in annual cohorts born between July 1975 and June 1988, the incidence among children in a given birth cohort was calculated by dividing the number of cases of hepatocellular carcinoma by the total number of person-years observed when the subjects were 6 to 14 years old. The effect of the nationwide vaccination program on the incidence of hepatocellular carcinoma was assessed by Poisson regression analysis, with control for year of birth (before or after July 1984), age, and vaccination status.
Results
The average incidence of hepatocellular carcinoma in children 6 to 14 years of age from 1981 to 1986 was 0.70 per 100,000 children (range, 0.65 to 0.78). The average incidence declined to 0.57 (range, 0.48 to 0.62) for the period from 1986 to 1990 and to 0.36 for the period from 1990 to 1994 (range, 0.23 to 0.48). The ratio of the average incidence in the period from 1986 to 1990 to that in the period from 1982 to 1986 was 0.81. This decline may have been due to the herd immunity that resulted from the mass-vaccination program and the vaccination of preschool-age children. The ratio of the incidence in the 1990-to-1994 period to that in the 1986-to-1990 period was 0.63. This faster decline was attributed to the direct effect of mass vaccination. The incidence from 1990 to 1994 was significantly lower than that from 1981 to 1990 (P<0.01) (Table 2Table 2
Annual Incidence of Hepatocellular Carcinoma (HCC) and Brain Tumor in Children 6 to 14 Years of Age.). The age-adjusted relative risk of hepatocellular carcinoma after as compared with before July 1990 was 0.33 (P<0.001).The mortality rate in children with hepatocellular carcinoma showed a parallel decline (Table 2). The age-adjusted relative risk of death after as compared with before July 1990 was 0.51 (P<0.001).
In contrast, the incidence of brain tumors in children 6 to 14 years old did not show a similar decrease during the period of observation, according to the same registration system (Table 2). The overall incidence of childhood cancer also did not show such a decrease during this period (data not shown). By contrast, the incidence of liver cancer in people over 14 years of age increased from 11.11 to 25.82 per 100,000 population from 1981 to 1992 (Table 3Table 3
Annual Incidence of Liver Cancer per 100,000 People over 14 or under 6 Years of Age.). The incidence of liver cancer in children up to five years of age changed little during the same period (Table 3). The age-adjusted relative risk of liver cancer in children up to five years of age after as compared with before July 1984 was 0.97 (P = 0.91).An analysis of the incidence of liver cancer according to year of birth showed that the incidence among children 6 to 14 years old declined from 0.64 per 100,000 person-years for the cohort born between July 1975 and June 1976 to 0.1 per 100,000 person-years for the cohort born between July 1985 and June 1986 (Figure 1Figure 1
Comparison of the Incidence of Liver Cancer in Children 6 to 14 and 0 to 5 Years of Age, According to Birth Cohort.). However, the incidence among children up to five years of age did not decline for the cohorts born from 1974 to 1986 (Figure 1). There was a slow decline in the incidence of hepatocellular carcinoma among children 6 to 14 years old who were born before the start of the vaccination program (between 1980 and 1984) and a faster decline among those born after the start of the program (between 1984 and 1988) (Figure 1). The Poisson regression analysis showed that the relative risk of liver cancer was 0.34 in children 6 to 14 years old born after the implementation of the vaccination program, as compared with those born before the program, after adjustment for age and year of birth (P = 0.03). From 1974 to 1984, hepatocellular carcinoma was diagnosed in a total of 82 children among Taiwan's approximately 15.7 million children who were between the ages of six and nine years at any time during this period (0.52 per 100,000). From 1984 to 1986, hepatocellular carcinoma was diagnosed in only three children between the ages of six and nine among a population of about 2.3 million (0.13 per 100,000) (P<0.001) (Table 4Table 4
Incidence of Liver Cancer per 100,000 Children in Birth Cohorts Determined According to the Date of Implementation of the Hepatitis B Vaccination Program.). These three children, all boys born in 1985, received four doses each of hepatitis B vaccine. Two were born to HBsAg-carrier mothers and received hepatitis B immune globulin at birth. Both tested seropositive for HBsAg and hepatitis B e antibody when hepatocellular carcinoma was diagnosed. The third child and his mother consistently tested seronegative for HBsAg. Hepatocellular carcinoma was confirmed in the child by histologic examination. Polymerase-chain-reaction assays detected HBV genome in both the tumorous and nontumorous liver tissue of this child. All three children had markedly elevated serum alpha-fetoprotein levels and space-occupying lesions in the liver. All three died.Discussion
This study in Taiwan shows that 6 to 10 years after the initiation of the hepatitis B mass-vaccination program, the incidence of childhood hepatocellular carcinoma declined significantly. These data are evidence that prevention of a viral infection in a population can reduce the incidence of a specific cancer.
Three lines of evidence support our finding of a decline in the rate of childhood hepatocellular carcinoma after the initiation of the Taiwanese hepatitis B vaccination program. First, data from three different registration systems consistently showed similar trends toward decreases in childhood hepatocellular carcinoma during the observation period from 1981 to 1994 (Table 2). Second, the annual incidence of another childhood cancer — namely, brain tumors in children of the same age — remained similar during the same period. The incidence of liver cancer in children younger than six years also did not decrease. This suggests that the decrease in childhood hepatocellular carcinoma is specific. Third, the incidence of hepatocellular carcinoma decreased in children but gradually increased in people older than 14 years between 1981 and 1993. The increase in incidence in adults is reasonable, since diagnostic accuracy has improved and screening programs using ultrasonography and alpha-fetoprotein have been launched for early detection of liver cancer in high-risk subjects.6 The increasing life span of the population and the growing role of hepatitis C virus18 may also contribute to the increase of liver cancer in adults.
A decline in the incidence of liver cancer has been observed since 1986 among children 6 to 14 years old who were born between 1980 and 1984, before the start of the national vaccination program. This decline is paralleled by a decrease in the rate of HBsAg carriage among children born before the program was launched (Table 1). The herd immunity resulting from the mass vaccination of children in the highly infectious younger birth cohorts may have reduced the rate of horizontal HBV infection among unvaccinated older children. The reduction in the HBsAg-seropositivity rate among children in unvaccinated cohorts reflects a decline of a similar magnitude in the incidence of hepatocellular carcinoma. The decline in incidence among children born before the launch of the national vaccination program may be attributable to the herd immunity resulting from the program. The extension of the vaccination program to preschool children might also have contributed to the decline in the rate of HBsAg carriage and in the rate of hepatocellular carcinoma in children born before July 1984.
Perinatal mother-to-infant transmission of HBV is an important factor in the rate of HBsAg carriage. It accounts for 40 to 50 percent of HBsAg carriers in Taiwan.19 These perinatally infected HBsAg carriers are at risk for hepatocellular carcinoma as adults20 or children.7,8 The HBsAg-positivity rate has been shown to be as high as 94 percent among the mothers of children with hepatocellular carcinoma in Taiwan.7 Similarly, perinatal transmission of woodchuck hepatitis virus has been reported to cause liver cancer.5
The Taiwanese program of vaccination to reduce the perinatal transmission of HBV has been carried out successfully since 1984. According to our previous observations in Taiwan,7,8,14 the earliest time at which the effect of the hepatitis B vaccination program on childhood hepatocellular carcinoma can be seen is 1990, six years after the launch of the program. If the efficacy of the program were 100 percent, with a coverage of 100 percent, and childhood hepatocellular carcinoma were caused solely by HBV, there should be no hepatocellular carcinoma in children born after July 1984. Children who missed the vaccination program or failed to respond to the vaccine could still have hepatocellular carcinoma later on. In fact, hepatocellular carcinoma was found in three children who were born after July 1984 and had received hepatitis B immunization through the national program. The effect of HBV vaccination on the declining incidence of childhood hepatocellular carcinoma was most evident when different birth cohorts were analyzed (Table 4).
This HBV vaccination program has been integrated into the Expanded Programme on Immunization for Taiwanese infants since July 1986. We strongly recommend that hepatitis B vaccination be integrated into the worldwide Expanded Programme on Immunization to interrupt perinatal and early horizontal transmission of HBV and the subsequent development of chronic liver disease. Such measures are important and urgent, particularly in areas with a high incidence of HBV infection and hepatocellular carcinoma.
Since HBV-associated liver cancer peaks among people 50 to 60 years of age in Taiwan,6 continued monitoring of the incidence of hepatocellular carcinoma among children and adults is necessary to further document the decrease in cases of hepatocellular carcinoma in association with the initiation of the hepatitis B mass-vaccination program.
Supported by grants (DOH85-HR-518 and 86-HR-518) from the National Health Research Institute, Taiwan.
Source Information
From the Department of Pediatrics (M.-H.C.) and the Hepatitis Research Center (D.-S.C.), College of Medicine, and the Graduate Institute of Epidemiology, College of Public Health (C.-J.C., W.-Y.S.), National Taiwan University, Taipei; the Department of Health, Executive Yuan, Taipei (M.-S.L., H.-M.H.); the Department of Pediatrics, Veterans General Hospital, Taipei (T.-C.W.); the Department of Pediatrics, Chang-Gung Children's Hospital, Linkou, Taoyuan (M.-S.K.); and the Department of Pediatrics, Mackay Memorial Hospital, Taipei (D.-C.L.) — all in Taiwan.
Address reprint requests to Dr. Chang at the Department of Pediatrics, National Taiwan University Hospital, No. 7, Chung-Shan South Rd., Taipei, Taiwan.
Other members of the Taiwan Childhood Hepatoma Study Group are listed in the Appendix.
Appendix
The following additional institutions and investigators participated in the Taiwan Childhood Hepatoma Study Group: C.-S. Chi, Veterans General Hospital, Taichung; S.-N. Cheng, Tri-Service General Hospital; C.-J. Tsai, Kaoshiung Medical College; L.-H. Lin, Cathay General Hospital; M.-W. Lai, Taoyuan Provincial Hospital; M.-T. Cheng, Chang-hua Christian Hospital; A.-C. Chen, National Cheng-Kung University Hospital; W.-C. Lee, Sa-lu Kong-Ten General Hospital; T.-C. Tsai, Hua-lien Tzu-Chi Buddhist Hospital; Y.-H. Tsai, Taiwan Provincial Taipei Hospital; C.-C. Wu, St. Mary's Hospital; S.-F. Wu, China Medical College Hospital; S.-C. Huang, Chang-Gung Children's Hospital, Kaohsiung; and U.-P. Ling, Chung-Shan Medical College Hospital.
- References
References
1
Popper H ,Gerber MA ,Thung SN . The relation of hepatocellular carcinoma to infection with hepatitis B and related viruses in man and animals. Hepatology 1982;2:Suppl:1S-9S
CrossRef | Web of Science2
Beasley RP ,Hwang LY ,Lin CC ,Chien CS . Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-1133
CrossRef | Web of Science | Medline3
Larouze B ,Saimot G ,Lustbader ED ,London WT ,Werner BG ,Payet M . Host response to hepatitis-B infection in patients with primary hepatic carcinoma and their families: a case/control study in Senegal, West Africa. Lancet 1976;2:534-538
CrossRef | Web of Science | Medline4
Brechot C ,Hadchouel M ,Scotto J , et al. Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet 1981;2:765-768
CrossRef | Web of Science | Medline5
Popper H ,Roth L ,Purcell RH ,Tennant BC ,Gerin JL . Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987;84:866-870
CrossRef | Web of Science | Medline6
Chen D-S. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K, Ishak KG, eds. Neoplasms of the liver. Tokyo: Springer-Verlag, 1987:71-80.
7
Chang MH ,Chen DS ,Hsu HC ,Hsu HY ,Lee CY . Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64:2377-2380
CrossRef | Web of Science | Medline8
Wu TC ,Tong MJ ,Hwang B ,Lee SD ,Hu MM . Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology 1987;7:46-48
CrossRef | Web of Science | Medline9
Chang MH ,Chen PJ ,Chen JY , et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology 1991;13:316-320
CrossRef | Web of Science | Medline10
Chen DS ,Hsu NHM ,Sung JL , et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987;257:2597-2603
CrossRef | Web of Science | Medline11
Hsu HM ,Chen DS ,Chuang CH , et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-2235
CrossRef | Web of Science | Medline12
Chen HL ,Chang MH ,Hsu HY , et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-908
CrossRef | Web of Science | Medline13
Kuo CY ,Liu HC ,Chang MH , et al. Hepatoblastoma in infancy and childhood: a clinical and pathological study of 32 cases. Acta Paediatr Sin 1991;32:79-8714
Ni YH ,Chang MH ,Hsu HY , et al. Hepatocellular carcinoma in childhood: clinical manifestations and prognosis. Cancer 1991;68:1737-1741
CrossRef | Web of Science | Medline15
Capture-recapture model. In: Selvin S. Practical biostatistical methods. Belmont, Calif.: Duxbury Press, 1995:342-9.
16
Manual of the international statistical classification of diseases, injuries, and causes of death. 1975 Rev. Vol. 1. Geneva: World Health Organization, 1977.
17
Poisson regression analysis. In: Selvin S. Practical biostatistical methods. Belmont, Calif.: Duxbury Press, 1995:455-90.
18
Chen DS ,Kuo GC ,Sung JL , et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:817-822
CrossRef | Web of Science | Medline19
Stevens CE ,Beasley RP ,Tsui J ,Lee W-C . Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-774
Full Text | Web of Science | Medline20
Sung JL ,Chen DS . Maternal transmission of hepatitis B surface antigen in patients with hepatocellular carcinoma in Taiwan. Scand J Gastroenterol 1980;15:321-324
CrossRef | Web of Science | Medline
- Citing Articles (492)
Citing Articles
1
W.-J. Su, C.-C. Liu, D.-P. Liu, S.-F. Chen, J.-J. Huang, T.-C. Chan, M.-H. Chang. (2012) Effect of Age on the Incidence of Acute Hepatitis B After 25 Years of a Universal Newborn Hepatitis B Immunization Program in Taiwan. Journal of Infectious Diseases
CrossRef2
Joe B. Harford. (2012) Viral infections and human cancers: the legacy of Denis Burkitt. British Journal of Haematologyno-no
CrossRef3
Henry Lik-Yuen Chan, Vincent Wai-Sun Wong. 2012. Hepatitis B. , 540-563.
CrossRef4
Jorge A. Marrero. 2012. Hepatocellular Carcinoma. , 1005-1031.
CrossRef5
Hashem B. El-Serag, André Lechel, K. Lenhard Rudolph. 2012. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. , 142-156.
CrossRef6
Scott A. Elisofon, Maureen M.F. Jonas. 2012. Viral Hepatitis in Children. , 1257-1271.
CrossRef7
Sandra S. Chaves, Gayle Fischer, Justina Groeger, Priti R. Patel, Nicola D. Thompson, Eyasu H. Teshale, Kuartei Stevenson, Victor M. Yano, Gregory L. Armstrong, Taraz Samandari, Saleem Kamili, Jan Drobeniuc, Dale J. Hu. (2012) Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine
CrossRef8
Alejandro Forner, Carmen Ayuso, Jordi Bruix. 2011. Hepatocellular Carcinoma. , 978-989.
CrossRef9
Anna S. F. Lok, Francesco Negro. 2011. Hepatitis B and D. , 537-581.
CrossRef10
Tim F. Greten, Firouzeh Korangy. 2011. Is Immune Modulation a Possibility?. , 191-198.
CrossRef11
Hashem B. El-Serag. 2011. Are Patterns and Prevalence Changing?. , 1-10.
CrossRef12
Jia-Horng Kao. 2011. Control by Vaccination: Asian and Taiwan Experience. , 18-23.
CrossRef13
Rong-Nan Chien. (2011) Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?. Journal of Gastroenterology and Hepatology 26:12, 1699-1701
CrossRef14
Oi Ka Chan, Terence T. Lao, Stephen S.H. Suen, Tze Kin Lau, Tak Yeung Leung. (2011) Knowledge on hepatitis B infection among pregnant women in a high endemicity area. Patient Education and Counseling 85:3, 516-520
CrossRef15
Suzanne Wait, Ding-Shinn Chen. (2011) Towards the eradication of hepatitis B in Taiwan. The Kaohsiung Journal of Medical Sciences
CrossRef16
Zhuanbo Luo, Lanjuan Li, Bing Ruan. (2011) Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. International Journal of Infectious Diseases
CrossRef17
Luigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro. (2011) Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Review of Vaccines 10:11, 1569-1583
CrossRef18
Kar Neng Lai. (2011) Hepatitis-related renal disease. Future Virology 6:11, 1361-1376
CrossRef19
Chia-Feng Yen, Jin-Ding Lin. (2011) Factors influencing administration of hepatitis B vaccine to community-dwelling teenagers aged 12–18 with an intellectual disability. Research in Developmental Disabilities 32:6, 2943-2949
CrossRef20
Ke-Qin Hu, Calvin Q. Pan, Diane Goodwin. (2011) Barriers to Screening for Hepatitis B Virus Infection in Asian Americans. Digestive Diseases and Sciences 56:11, 3163-3171
CrossRef21
Stanislas Pol, Marion Corouge, Hélène Fontaine. (2011) Hepatitis B virus infection and pregnancy. Clinics and Research in Hepatology and Gastroenterology 35:10, 618-622
CrossRef22
Philip J. Johnson. (2011) Hepatobiliary tumours. Medicine 39:10, 630-633
CrossRef23
Brian J. McMahon, Lisa R. Bulkow, Rosalyn J. Singleton, James Williams, Mary Snowball, Chriss Homan, Alan J. Parkinson. (2011) Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54:3, 801-807
CrossRef24
Fang-Yeh Chu, Fu-Hsiung Su, Shu-Hsing Cheng, Yu-Shiang Lin, Chung-Yi Li, Chih-Ching Chien, Yu-Cheng Lin, Shuo-Ya Chiang. (2011) Hepatitis B surface antigen confirmatory testing for diagnosis of hepatitis b virus infection in Taiwan. Journal of Medical Virology 83:9, 1514-1521
CrossRef25
Usa Thisyakorn, May Montellano, Andrew Lane. (2011) Routine Newborn Hepatitis B Immunization. Infectious Diseases in Clinical Practice 19:5, 326-331
CrossRef26
Ryo Nagashio, Eri Arai, Hidenori Ojima, Tomoo Kosuge, Yutaka Kondo, Yae Kanai. (2011) Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. International Journal of Cancer 129:5, 1170-1179
CrossRef27
Christopher V. Chambers. (2011) Cancer Vaccines. Primary Care: Clinics in Office Practice
CrossRef28
Richard Wilber, Bruce Kreter, Marc Bifano, Stephanie Danetz, Lois Lehman-McKeeman, Daniel J. Tenney, Nicholas Meanwell, Robert Zahler, Helena Brett-Smith. 2011. Discovery and Development of Entecavir. , 401-416.
CrossRef29
Ding-Shinn Chen. (2011) Fighting against viral hepatitis: Lessons from Taiwan. Hepatology 54:2, 381-392
CrossRef30
L. P. SHEN, Y. ZHANG, F. WANG, S. ZHANG, J. Y. YANG, K. X. FANG, T. YU, X. Y. WANG, W. Y. ZHANG, S. L. BI. (2011) Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemiology and Infection 139:08, 1159-1165
CrossRef31
Vincent K. Tuohy, Ritika Jaini. (2011) Prophylactic cancer vaccination by targeting functional non-self. Annals of Medicine 43:5, 356-365
CrossRef32
Xiangwei Wu, Sherri Patterson, Ernest Hawk. (2011) Chemoprevention – History and general principles. Best Practice & Research Clinical Gastroenterology 25:4-5, 445-459
CrossRef33
Gerd Lipowsky, Martin F. Bachmann. 2011. Design and Development of Recombinant Vaccines with Viral Properties. , 19-63.
CrossRef34
E. Leuridan, P. Van Damme. (2011) Hepatitis B and the Need for a Booster Dose. Clinical Infectious Diseases 53:1, 68-75
CrossRef35
Valentina Santi, Daniela Buccione, Antonio Di Micoli, Gianluca Fatti, Marta Frigerio, Fabio Farinati, Paolo Del Poggio, Gianludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Edoardo Giovanni Giannini, Eugenio Caturelli, Maria Chiaramonte, Mauro Bernardi, Franco Trevisani. (2011) The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology
CrossRef36
Ching-Chiang Lin, Chun-Yuh Yang, Ching-Tang Shih, Bai-Hsiun Chen, Yeou-Lih Huang. (2011) Waning immunity and booster responses in nursing and medical technology students who had received plasma-derived or recombinant hepatitis B vaccine during infancy. American Journal of Infection Control 39:5, 408-414
CrossRef37
S. De Flora, P. Bonanni. (2011) The prevention of infection-associated cancers. Carcinogenesis 32:6, 787-795
CrossRef38
Elena Vezali, Alessio Aghemo, Pietro Lampertico, Massimo Colombo. (2011) Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. Clinics and Research in Hepatology and Gastroenterology 35:6-7, 455-464
CrossRef39
Augusto Villanueva, Josep M. Llovet. (2011) Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology 140:5, 1410-1426
CrossRef40
Anna S. F. Lok. 2011. Hepatitis B. , 367-392.
CrossRef41
Yun Xia, Hui Luo, Jian Ping Liu, Christian Gluud, Yun Xia. 2011. Phyllanthus species for chronic hepatitis B virus infection. .
CrossRef42
Li-Min Huang, Chun-Yi Lu, Ding-Shinn Chen. (2011) Hepatitis B virus infection, its sequelae, and prevention by vaccination. Current Opinion in Immunology 23:2, 237-243
CrossRef43
Chien-Jen Chen, Hwai-I Yang. (2011) Natural history of chronic hepatitis B REVEALed. Journal of Gastroenterology and Hepatology 26:4, 628-638
CrossRef44
Ying-Ju Lin, Yu-Ching Lan, Lei Wan, Ting-Hsu Lin, Da-Yuan Chen, Chang-Hai Tsai, Chiu-Shong Liu, Kai-Chung Hsueh, Fuu-Jen Tsai. (2011) Serological surveillance and IL-10 genetic variants on anti-HBs titers: Hepatitis B vaccination 20years after neonatal immunization in Taiwan. Clinica Chimica Acta 412:9-10, 766-773
CrossRef45
Guo-Rong Han, Min-Kai Cao, Wei Zhao, Hong-Xiu Jiang, Cui-Min Wang, Shu-Fen Bai, Xin Yue, Gen-Ju Wang, Xun Tang, Zhi-Xun Fang. (2011) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology
CrossRef46
Arie J Zuckerman. 2011. Hepatitis Viruses. .
CrossRef47
M. Cornberg, M.P. Manns. (2011) Prävention der Virushepatitis A bis E. Der Internist 52:3, 250-264
CrossRef48
Hitoshi Tajiri, Hideo Tanaka, Stephen Brooks, Tomoko Takano. (2011) Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes & Control 22:3, 523-527
CrossRef49
Corey Casper. (2011) The Increasing Burden of HIV-Associated Malignancies in Resource-Limited Regions. Annual Review of Medicine 62:1, 157-170
CrossRef50
Wan-Hsin Wen, Huey-Ling Chen, Yen-Hsuan Ni, Hong-Yuan Hsu, Jia-Horng Kao, Fu-Chang Hu, Mei-Hwei Chang. (2011) Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 53:2, 429-436
CrossRef51
T.-H. Su, P.-J. Chen, T.-C. Chen, H.-R. Cheng, L. Li, K.-S. Lin, J.-H. Kao, D.-S. Chen, C.-J. Liu. (2011) The clinical significance of occult hepatitis B transfusion in Taiwan - a look-back study. Transfusion Medicine 21:1, 33-41
CrossRef52
Jie Chen, Zhenglun Liang, Fengmin Lu, Xin Fang, Shuang Liu, Ying Zeng, Fengcai Zhu, Xiangmei Chen, Tao Shen, Jie Li, Hui Zhuang. (2011) Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 29:4, 706-711
CrossRef53
Luisa Romano', Sara Paladini, Pierre Van Damme, Alessandro R. Zanetti. (2011) The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease 43, S2-S7
CrossRef54
Angela Gentile, Veronica Umido, Paola Czerniuk, Josefina Nacul, Mauricio Seigelchifer, Anne Katrin Hilbert, Ursula Yela, Christian Herzog, Ursula Aeberhard, Christian Spyr. (2011) Immunogenicity and reactogenicity of a combined fully liquid DTPw–HepB–Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine. International Journal of Infectious Diseases 15:1, e24-e29
CrossRef55
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P. Restifo. (2011) Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1, 27-44
CrossRef56
Glen A. Lutchman, Mindie A. Nguyen. (2011) Screening for Hepatocellular Carcinoma After HBsAg Clearance Age Before Cirrhosis?. Journal of Clinical Gastroenterology 45:1, 4-5
CrossRef57
Rong-Hwa Jan, Yu-Li Lin, Li-Kuang Chen, Miao-Tzu Huang, Li-Chieh Wang, Bor-Luen Chiang. (2011) Hepatitis B virus surface antigen can activate dendritic cells and modulate T helper type immune response. Microbiology and Immunology 55:1, 51-59
CrossRef58
So Young Kwon, Chang Hong Lee. (2011) Epidemiology and prevention of hepatitis B virus infection. The Korean Journal of Hepatology 17:2, 87
CrossRef59
J.-L. Raoul, M. Latournerie, A. Guillygomarc’h, K. Boudjema, O. Audrain, É. Boucher. (2011) Carcinoma hepatocelular. EMC - Tratado de Medicina 15:3, 1-9
CrossRef60
Juan J. Picazo, Javier de Arístegui Fernández, Jose M. Arteagoitia Axpe, Dolores Barranco Ordóñez, Aurelio Barricarte Gurrea, Xavier Bosch José, Javier Díez Domingo, Fernando González Romo, Teresa Hernández-Sampelayo Matos, Jesús Ruiz Contreras, Lluís Salleras. (2011) Evidencias científicas disponibles sobre la seguridad de las vacunas. Vacunas 12:1, 3-34
CrossRef61
Kumaresan Yogeswaran, Scott K. Fung. (2011) Chronic hepatitis B in pregnancy: unique challenges and opportunities. The Korean Journal of Hepatology 17:1, 1
CrossRef62
Ching-Hung Lin, Yong-Chen Chen, Chun-Ju Chiang, Yen-Shen Lu, Kuan-Ting Kuo, Chiun-Sheng Huang, Wen-Fang Cheng, Mei-Shu Lai, San-Lin You, Ann-Lii Cheng. (2011) The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. International Journal of Cancern/a-n/a
CrossRef63
Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn. (2011) Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology 81:s1, 41-49
CrossRef64
Kwong-Ming Kee, Sheng-Nan Lu. (2011) Hospital- and Community-Based Screenings for Hepatocellular Carcinoma in Taiwan. Oncology 81:s1, 36-40
CrossRef65
Patrick S. Moore, Yuan Chang. (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Reviews Cancer 10:12, 878-889
CrossRef66
Ju Dong Yang, Lewis R. Roberts. (2010) Epidemiology and Management of Hepatocellular Carcinoma. Infectious Disease Clinics of North America 24:4, 899-919
CrossRef67
John T. Schiller, Douglas R. Lowy. (2010) Vaccines to Prevent Infections by Oncoviruses *. Annual Review of Microbiology 64:1, 23-41
CrossRef68
Augusto Villanueva, Pippa Newell, Yujin Hoshida. (2010) Inherited hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 24:5, 725-734
CrossRef69
Penelope Brock, Derek J. Roebuck, Jack Plaschkes. 2010. Hepatic Tumors. , 258-274.
CrossRef70
Amelia J. Hessheimer, Alejandro Forner, María Varela, Jordi Bruix. (2010) Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 22:10, 1239-1244
CrossRef71
Chien Peter Chen, Daphne Haas-Kogan. (2010) Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 10:7, 883-895
CrossRef72
Massimo Colombo, Massimo Iavarone. 2010. Hepatocellular Carcinoma. , 650-660.
CrossRef73
R. Vilana, A. Forner, Á. García, C. Ayuso, C. Bru. (2010) Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica
. Radiología 52:5, 385-398
CrossRef74
Brian J. McMahon. (2010) Natural History of Chronic Hepatitis B. Clinics in Liver Disease 14:3, 381-396
CrossRef75
Michelle Lai, Yun-Fan Liaw. (2010) Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 14:3, 531-546
CrossRef76
S. H. JEONG, H. W. YIM, S. H. YOON, Y. M. JEE, S. H. BAE, W. C. LEE. (2010) Changes in the intrafamilial transmission of hepatitis B virus after introduction of a hepatitis B vaccination programme in Korea. Epidemiology and Infection 138:08, 1090-1095
CrossRef77
Mei Hwei Chang. (2010) Hepatitis B Vaccination: Disease and Cancer Prevention—A Taiwanese Experience. Clinics in Liver Disease 14:3, 521-530
CrossRef78
Helena Nordenstedt, Donna L. White, Hashem B. El-Serag. (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease 42, S206-S214
CrossRef79
Beatrijs A. Seinstra, Otto M. Delden, Karel J. Erpecum, Richard Hillegersberg, Willem P. Th. M. Mali, Maurice A. A. J. Bosch. (2010) Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. Insights into Imaging 1:3, 167-181
CrossRef80
Firouzeh Korangy, Bastian Höchst, Michael P Manns, Tim F Greten. (2010) Immunotherapy of hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 4:3, 345-353
CrossRef81
Alajos Pár. (2010) Hepatitis B-vírus- (HBV-) infekció és hepatocarcinogenesis. Orvosi Hetilap 151:26, 1045-1053
CrossRef82
Jerri do Carmo Caldeira, Alexander Medford, Rhonda C. Kines, Christopher A. Lino, John T. Schiller, Bryce Chackerian, David S. Peabody. (2010) Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28:27, 4384-4393
CrossRef83
CHIEN-YI CHEN, MEI-HWEI CHANG. (2010) HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. Fetal and Maternal Medicine Review 21:02, 89-113
CrossRef84
S. S. H. Suen, T. T. Lao, D. S. Sahota, T. K. Lau, T. Y. Leung. (2010) Implications of the relationship between maternal age and parity with hepatitis B carrier status in a high endemicity area. Journal of Viral Hepatitis 17:5, 372-378
CrossRef85
Chyi-Feng Jan, Kuo-Chin Huang, Yin-Chu Chien, Donald E. Greydanus, H. Dele Davies, Tai-Yuan Chiu, Li-Min Huang, Chien-Jen Chen, Ding-Shinn Chen. (2010) Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 51:5, 1547-1554
CrossRef86
Vincent Wai-Sun Wong, Joseph Jao-Yiu Sung. (2010) Impact of Antiviral Therapy on Risk of Hepatocellular Carcinoma. Current Hepatitis Reports 9:2, 47-52
CrossRef87
(2010) Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology 25:4, 657-663
CrossRef88
Stephen C. Hadler, Jane F. Seward. 2010. Immunoprophylaxis of Viral Diseases. .
CrossRef89
Giuseppe Del Giudice, Rino Rappuoli. 2010. Adjuvants and Subunit Vaccines. .
CrossRef90
Graham A. Colditz, Philip R. Taylor. (2010) Prevention Trials: Their Place in How We Understand the Value of Prevention Strategies. Annual Review of Public Health 31:1, 105-120
CrossRef91
F. M. Lu, T. Li, S. Liu, H. Zhuang. (2010) Epidemiology and prevention of hepatitis B virus infection in China. Journal of Viral Hepatitis 17, 4-9
CrossRef92
Damodar Janmanchi, Ya Ping Tseng, Kuei-Chen Wang, Ray Ling Huang, Chih Hsiu Lin, Sheau Farn Yeh. (2010) Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. Bioorganic & Medicinal Chemistry 18:3, 1213-1226
CrossRef93
Ching-Liang Lu, Hui-Chu Lang, Jiing-Chyuan Luo, Chun-Chu Liu, Han-Chieh Lin, Full-Young Chang, Shou-Dong Lee. (2010) Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes & Control 21:2, 269-274
CrossRef94
Helen S. Te, Donald M. Jensen. (2010) Epidemiology of Hepatitis B and C Viruses: A Global Overview. Clinics in Liver Disease 14:1, 1-21
CrossRef95
Ding-Shinn Chen. (2010) Toward elimination and eradication of hepatitis B. Journal of Gastroenterology and Hepatology 25:1, 19-25
CrossRef96
Stephanie R. Bialek, Louisa Helgenberger, Gayle E. Fischer, William A. Bower, Mailynn Konelios, Jean-Paul Chaine, Gregory Armstrong, Ian T. Williams, Beth P. Bell. (2010) Impact of Routine Hepatitis B Immunization on the Prevalence of Chronic Hepatitis B Virus Infection in the Marshall Islands and the Federated States of Micronesia. The Pediatric Infectious Disease Journal 29:1, 18-22
CrossRef97
Ching-Feng Lin, Shiing-Jer Twu, Ping-Ho Chen, Jror-Serk Cheng, Jung-Der Wang. (2010) Prevalence and Determinants of Hepatitis B Antigenemia in 15 007 Inmates in Taiwan. Journal of Epidemiology 20:3, 231-236
CrossRef98
Ping-ping Bao, Ying Zheng, Kai Gu, Chun-fang Wang, Chun-xiao Wu, Fan Jin, Wei Lu. (2010) Trends in childhood cancer incidence and mortality in urban Shanghai, 1973â2005. Pediatric Blood & Cancern/a-n/a
CrossRef99
R. Vilana, A. Forner, Á. García, C. Ayuso, C. Bru. (2010) Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. Radiología (English Edition) 52:5, 385-398
CrossRef100
Eri Arai, Saori Ushijima, Masahiro Gotoh, Hidenori Ojima, Tomoo Kosuge, Fumie Hosoda, Tatsuhiro Shibata, Tadashi Kondo, Sana Yokoi, Issei Imoto, Johji Inazawa, Setsuo Hirohashi, Yae Kanai. (2009) Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. International Journal of Cancer 125:12, 2854-2862
CrossRef101
Amelie Plymoth, Simonetta Viviani, Pierre Hainaut. (2009) Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: Perspectives for global liver cancer prevention. Cancer Letters 286:1, 15-21
CrossRef102
Georg W. Bornkamm. (2009) Epstein–Barr virus and its role in the pathogenesis of Burkitt's lymphoma: An unresolved issue. Seminars in Cancer Biology 19:6, 351-365
CrossRef103
Wei-Wen Su, Chien-Hung Chen, Hans Hsienhong Lin, Sheng-Shun Yang, Ting-Tsung Chang, Ken-Sheng Cheng, Jaw-Ching Wu, Shun-Sheng Wu, Chuan-Mo Lee, Chi-Sin Changchien, Chien-Jen Chen, Jin-Chuan Sheu, Ding-Shinn Chen, Sheng-Nan Lu. (2009) Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatology International 3:4, 537-543
CrossRef104
Nancy Leung. (2009) Chronic hepatitis B in Asian women of childbearing age. Hepatology International 3:S1, 24-31
CrossRef105
Iwona Mozer-Lisewska, Anna Mania, Wojciech Służewski, Paweł Kemnitz, Joanna Prusinowska, Arleta Kowala-Piaskowska, Magdalena Figlerowicz. (2009) Factors influencing clinical course and histological findings in children with chronic hepatitis B. European Journal of Gastroenterology & Hepatology 21:12, 1400-1406
CrossRef106
Kenji Abe, Swan N. Thung, Han-Chieh Wu, Tung Thanh Tran, Phuc Le Hoang, Khai Dinh Truong, Ayano Inui, Ja June Jang, Ih-Jen Su. (2009) Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Science 100:12, 2249-2254
CrossRef107
Donald Poon, Benjamin O Anderson, Li-Tzong Chen, Koichi Tanaka, Wan Yee Lau, Eric Van Cutsem, Harjit Singh, Wan Cheng Chow, London Lucien Ooi, Pierce Chow, Maung Win Khin, Wen Hsin Koo. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1111-1118
CrossRef108
J. Fung, C.-L. Lai, M.-F. Yuen. (2009) Hepatitis B and C virus-related carcinogenesis. Clinical Microbiology and Infection 15:11, 964-970
CrossRef109
G. Pappas. (2009) Infectious causes of cancer: an evolving educational saga. Clinical Microbiology and Infection 15:11, 961-963
CrossRef110
Shubham Shrivastava, Kavita S. Lole, Anuradha S. Tripathy, Umesh S. Shaligram, Vidya A. Arankalle. (2009) Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach. Vaccine 27:47, 6582-6588
CrossRef111
John Jenn-Yenn Lu, Chi-Chia Cheng, Shieu-Ming Chou, Chang-Bor Hor, Yi-Chen Yang, Hsiang-Ling Wang. (2009) Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine 27:47, 6613-6618
CrossRef112
Xiaofeng Liang, Shengli Bi, Weizhong Yang, Longde Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen Wang, Hui Zheng, Feng Wang, Jing Guo, Zhiyuan Jia, Jingchen Ma, Huaqing Wang, Huiming Luo, Li Li, Shuigao Jin, Stephen C. Hadler, Yu Wang. (2009) Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine 27:47, 6550-6557
CrossRef113
M.-H. Chang, S.-L. You, C.-J. Chen, C.-J. Liu, C.-M. Lee, S.-M. Lin, H.-C. Chu, T.-C. Wu, S.-S. Yang, H.-S. Kuo, D.-S. Chen, . (2009) Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. JNCI Journal of the National Cancer Institute 101:19, 1348-1355
CrossRef114
Mark Thursz, Graham S. Cooke, Andrew J. Hall. (2009) Hepatitis B treatment in resource poor settings: time for action. Tropical Medicine & International Health
CrossRef115
James Fung. (2009) Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. Expert Review of Anti-infective Therapy 7:8, 945-949
CrossRef116
Carrie M. Shuler, Anthony E. Fiore, Ruth Neeman, Beth P. Bell, Wendi Kuhnert, Sandra Watkins, Kimberly Kilgour, Kathryn E. Arnold. (2009) Reduction in hepatitis B virus seroprevalence among U.S.-born children of foreign-born Asian parents—Benefit of universal infant hepatitis B vaccination. Vaccine 27:43, 5942-5947
CrossRef117
Kuan-Ta Wu, Kun-Ming Chung, I.-Che Feng, Ming-Jen Sheu, Hsing-Tao Kuo, Lok-Beng Koay, Chin-Yih Lin, Ling-Yu Tang, Sun-Lung Tsai. (2009) Acute hepatitis E virus infection in Taiwan 2002-2006 revisited: PCR shows frequent co-infection with multiple hepatitis viruses. Journal of Medical Virology 81:10, 1734-1742
CrossRef118
Dennis John McCance. 2009. Oncogenic Viruses. .
CrossRef119
M. Magoni, K. D. Ekra, L. N. Aka, K. S. Sita, K. Kanga. (2009) Effectiveness of hepatitis-B vaccination in Ivory Coast: the case of the Grand Bassam health district. Annals of Tropical Medicine and Parasitology 103:6, 519-527
CrossRef120
Ying Dong, She-Lan Liu, Xiang-Jun Zhai, Feng-Cai Zhu, Hao Pan, Jia-xi Yu, Yin-zhong Chen, Yi-Rui Xie, Xiao-Yu Zhang, Hong-Mei Zhang, Lan-Juan Li, Hua Wang, Bing Ruan. (2009) A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China. Journal of Medical Virology 81:9, 1517-1524
CrossRef121
Mohamed IF Shariff, I Jane Cox, Asmaa I Gomaa, Shahid A Khan, Wladyslaw Gedroyc, Simon D Taylor-Robinson. (2009) Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 3:4, 353-367
CrossRef122
Watcharasak Chotiyaputta, Anna S. F. Lok. (2009) Hepatitis B virus variants. Nature Reviews Gastroenterology & Hepatology 6:8, 453-462
CrossRef123
Chung-Ren Su, Sheau Farn Yeh, Chih Miem Liu, Amooru G. Damu, Tsung-Hsiao Kuo, Po-Cheng Chiang, Kenneth F. Bastow, Kuo-Hsiung Lee, Tian-Shung Wu. (2009) Anti-HBV and cytotoxic activities of pyranocoumarin derivatives. Bioorganic & Medicinal Chemistry 17:16, 6137-6143
CrossRef124
Seng Gee Lim, Rosmawati Mohammed, Man-Fung Yuen, Jia-Horng Kao. (2009) Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of Gastroenterology and Hepatology 24:8, 1352-1357
CrossRef125
Hans Christian Spangenberg, Robert Thimme, Hubert E. Blum. (2009) Targeted therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 6:7, 423-432
CrossRef126
C. Verslype, E. Van Cutsem, M. Dicato, N. Arber, J. D. Berlin, D. Cunningham, A. De Gramont, E. Diaz-Rubio, M. Ducreux, T. Gruenberger, D. Haller, K. Haustermans, P. Hoff, D. Kerr, R. Labianca, M. Moore, B. Nordlinger, A. Ohtsu, P. Rougier, W. Scheithauer, H.-J. Schmoll, A. Sobrero, J. Tabernero, C. van de Velde. (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Annals of Oncology 20:Supplement 7, vii1-vii6
CrossRef127
Catherine de Martel, Silvia Franceschi. (2009) Infections and cancer: Established associations and new hypotheses. Critical Reviews in Oncology/Hematology 70:3, 183-194
CrossRef128
Kazuhiro Kondo, Kazuo Chijiiwa. (2009) Surgical treatment for hepatocellular carcinoma in elderly patients. Aging Health 5:3, 333-343
CrossRef129
Long-Teng Lee, Hsiao-Yuan Huang, Kuo-Chin Huang, Ching-Yu Chen, Wen-Chung Lee. (2009) Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, 1976–2005. Annals of Epidemiology 19:5, 323-328
CrossRef130
Adrian M. Di Bisceglie. (2009) Hepatitis B and hepatocellular carcinoma. Hepatology 49:S5, S56-S60
CrossRef131
Chien-Jen Chen, Hwai-I Yang, Uchenna H. Iloeje, . (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:S5, S72-S84
CrossRef132
R. Liang. (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:14, 3147-3153
CrossRef133
Ding-Shinn Chen. (2009) Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. Journal of Hepatology 50:4, 805-816
CrossRef134
P Ocama, S Nambooze, C K Opio, M S Shiels, H R Wabinga, G D Kirk. (2009) Trends in the incidence of primary liver cancer in Central Uganda, 1960–1980 and 1991–2005. British Journal of Cancer 100:5, 799-802
CrossRef135
William N. William, John V. Heymach, Edward S. Kim, Scott M. Lippman. (2009) Molecular targets for cancer chemoprevention. Nature Reviews Drug Discovery 8:3, 213-225
CrossRef136
Lluís Castells. (2009) Vacuna contra el virus de la hepatitis B y enfermedad inflamatoria intestinal. Medicina Clínica 132:9, 348-350
CrossRef137
She-Lan Liu, Ying Dong, Li Zhang, Min-Wei Li, Jian-er Wo, Li-Wei Lu, Zhen-Juan Chen, Yong-Zhong Wang, Bing Ruan. (2009) Influence of HBV gene heterogeneity on the failure of immunization with HBV vaccines in eastern China. Archives of Virology 154:3, 437-443
CrossRef138
Giuseppe Cabibbo, Federica Latteri, Michela Antonucci, Antonio Craxì. (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nature Clinical Practice Gastroenterology & Hepatology 6:3, 159-169
CrossRef139
Chih-Cheng Hsiao, Jiin-Haur Chuang, Mao-Ming Tiao, Jiunn-Ming Sheen, Chie-Song Shieh. (2009) Patterns of Hepatoblastoma and Hepatocellular Carcinoma in Children After Universal Hepatitis B Vaccination in Taiwan. Journal of Pediatric Hematology/Oncology 31:2, 91-96
CrossRef140
Hal B Jenson. (2009) Human papillomavirus vaccine: a paradigm shift for pediatricians. Current Opinion in Pediatrics 21:1, 112-121
CrossRef141
Alejandro Forner, Carmen Ayuso, María Isabel Real, Javier Sastre, Ricardo Robles, Bruno Sangro, María Varela, Manuel de la Mata, María Buti, Luís Martí-Bonmatí, Concepció Bru, Josep Tabernero, Josep M Llovet, Jordi Bruix. (2009) Diagnóstico y tratamiento del carcinoma hepatocelular. Medicina Clínica 132:7, 272-287
CrossRef142
Alicia Demirjian, Ofer Levy. (2009) Safety and efficacy of neonatal vaccination. European Journal of Immunology 39:1, 36-46
CrossRef143
Heon Ju Lee, Jong Ryul Eun, Chang Hyeong Lee, Jae Seok Hwang, Jeong Ill Suh, Byung Seok Kim, Byoung Kuk Jang. (2009) Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. The Korean Journal of Hepatology 15:2, 179
CrossRef144
Alajos Pár. (2009) A vírushepatitisek megelőzése és antivirális kezelése mint a hepatocellularis carcinoma (HCC) prevenciója. Orvosi Hetilap 150:1, 19-26
CrossRef145
Philip Johnson, Lucinda Billingham. (2009) Sorafenib for liver cancer: the horizon broadens. The Lancet Oncology 10:1, 4-5
CrossRef146
Nizar Ajjan. 2009. Acquisitions récentes en matière de vaccinations et vaccins du futur. , 207-301.
CrossRef147
Cihan Yurdaydin. (2008) Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 9:17, 3095-3109
CrossRef148
David J. Kramer. (2008) Invited commentary: Septic shock in acute liver failure. Journal of Critical Care 23:4, 473-474
CrossRef149
David Yiu-Kuen But, Ching-Lung Lai, Wei-Ling Lim, James Fung, Danny Ka-Ho Wong, Man-Fung Yuen. (2008) Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. Vaccine 26:51, 6587-6591
CrossRef150
Simon P. Dawson. (2008) Hepatocellular carcinoma and the ubiquitin–proteasome system. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1782:12, 775-784
CrossRef151
Scott M. Lippman. (2008) The Future of Molecular-Targeted Cancer Chemoprevention. Gastroenterology 135:6, 1834-1841
CrossRef152
Daniel Lavanchy. (2008) Chronic viral hepatitis as a public health issue in the world. Best Practice & Research Clinical Gastroenterology 22:6, 991-1008
CrossRef153
Tarik Asselah, Olivier Lada, Rami Moucari, Patrick Marcellin. (2008) Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 17:12, 1963-1974
CrossRef154
K. Itoh, A. Yamada, T. Mine, M. Noguchi. (2008) Recent Advances in Cancer Vaccines: An Overview. Japanese Journal of Clinical Oncology 39:2, 73-80
CrossRef155
Patricia Roxburgh, T. R. Jeffry Evans. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress?. Advances in Therapy 25:11, 1089-1104
CrossRef156
Alessandro R. Zanetti, Pierre Van Damme, Daniel Shouval. (2008) The global impact of vaccination against hepatitis B: A historical overview. Vaccine 26:49, 6266-6273
CrossRef157
Edmondo Falleti, Carlo Fabris, Pierluigi Toniutto, Elisabetta Fontanini, Annarosa Cussigh, Davide Bitetto, Ezio Fornasiere, Claudio Avellini, Rosalba Minisini, Mario Pirisi. (2008) TGF-β1 genotypes in cirrhosis: Relationship with the occurrence of liver cancer. Cytokine 44:2, 256-261
CrossRef158
H-T Jin, J-I Youn, S-Y Choi, S-H Seo, S-H Park, M-Y Song, S-H Yang, Y-C Sung. (2008) Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects. Cancer Gene Therapy 15:11, 693-702
CrossRef159
Koen Van Herck, Pierre Van Damme. (2008) Benefits of Early Hepatitis B Immunization Programs for Newborns and Infants. The Pediatric Infectious Disease Journal 27:10, 861-869
CrossRef160
Gaia Pocobelli, Linda S. Cook, Rollin Brant, Samuel S. Lee. (2008) Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver International 28:9, 1272-1279
CrossRef161
Stephanie R. Bialek, William A. Bower, Ryan Novak, Louisa Helgenberger, Steven B. Auerbach, Ian T. Williams, Beth P. Bell. (2008) Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth. The Pediatric Infectious Disease Journal 27:10, 881-885
CrossRef162
J. M. Llovet, A. Lok. (2008) Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute 100:16, 1121-1123
CrossRef163
W. T. Kassahun, J. Hauss. (2008) Management of combined hepatocellular and cholangiocarcinoma. International Journal of Clinical Practice 62:8, 1271-1278
CrossRef164
Y. H. Hu, C. L. Lin, Y. W. Huang, P. E. Liu, D.-F. Hwang. (2008) Dietary amino acid taurine ameliorates liver injury in chronic hepatitis patients. Amino Acids 35:2, 469-473
CrossRef165
Ke-Qin Hu. (2008) Hepatitis B Virus (HBV) Infection in Asian and Pacific Islander Americans (APIAs): How Can We Do Better for This Special Population. The American Journal of Gastroenterology 103:7, 1824-1833
CrossRef166
S. W. Moore, A. Davidson, G. P. Hadley, M. Kruger, J. Poole, D. Stones, L. Wainwright, G. Wessels. (2008) Malignant Liver Tumors in South African Children: A National Audit. World Journal of Surgery 32:7, 1389-1395
CrossRef167
Chang-Yin Lee, Yi-Chao Hsu, Jir-You Wang, Chien-Chih Chen, Jen-Hwey Chiu. (2008) Chemopreventive effect of selenium and Chinese medicinal herbs on N-nitrosobis(2-oxopropyl)amine-induced hepatocellular carcinoma in Syrian hamsters. Liver International 28:6, 841-855
CrossRef168
Van Thi Thuy Nguyen, Karina Razali, Janaki Amin, Matthew G Law, Gregory J Dore. (2008) Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. Journal of Gastroenterology and Hepatology 23:6, 922-929
CrossRef169
G Thomas Strickland, Samer S El-Kamary, Paul Klenerman, Alfredo Nicosia. (2008) Hepatitis C vaccine: supply and demand. The Lancet Infectious Diseases 8:6, 379-386
CrossRef170
Evelyn K Hsu, Karen F Murray. (2008) Hepatitis B and C in children. Nature Clinical Practice Gastroenterology & Hepatology 5:6, 311-320
CrossRef171
Hans Hsienhong Lin, Huei-Wen Chang Liao, Sheng-Kai Lin, Li-Yu Wang. (2008) HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Vaccine 26:27-28, 3414-3420
CrossRef172
Hans Christian Spangenberg, Robert Thimme, Hubert E Blum. (2008) Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2:3, 425-433
CrossRef173
F. Pons Renedo, J. de la Revilla Negro, J.L. Calleja Panero. (2008) Carcinoma hepatocelular. Medicine - Programa de Formación Médica Continuada Acreditado 10:12, 770-776
CrossRef174
Chun‐Yi Lu, Yen‐Hsuan Ni, Bor‐Luen Chiang, Pei‐Jer Chen, Mei‐Hwei Chang, Luan‐Yin Chang, Ih‐Jen Su, Hsu‐Sung Kuo, Li‐Min Huang, Ding‐Shinn Chen, Chin‐Yun Lee. (2008) Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15–18 Years after Neonatal Immunization. The Journal of Infectious Diseases 197:10, 1419-1426
CrossRef175
Donald Maxwell Parkin. (2008) The role of cancer registries in cancer control. International Journal of Clinical Oncology 13:2, 102-111
CrossRef176
Kathleen Strong, Colin Mathers, JoAnne Epping-Jordan, Serge Resnikoff, Andreas Ullrich. (2008) Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years?. European Journal of Cancer Prevention 17:2, 153-161
CrossRef177
A. Gervais, P. Longuet, C. Leport. (2008) A Success Story: Universal Vaccination in Italy--What Has to Be Done to Eradicate Residual Acute Hepatitis B?. Clinical Infectious Diseases 46:6, 876-877
CrossRef178
Rui Gao, Zhuan Liao, Zhao-Shen Li. (2008) Scientific publications in gastroenterology and hepatology journals from Chinese authors in various parts of North Asia: 10-year survey of literature. Journal of Gastroenterology and Hepatology 23:3, 374-378
CrossRef179
S-L Yen, T-Y Chiu, Y-C Lin, Y-C Lee, L-T Lee, K-C Huang. (2008) Obesity and hepatitis B infection are associated with increased risk of metabolic syndrome in university freshmen. International Journal of Obesity 32:3, 474-480
CrossRef180
Sérgio Júlio Fernandes, Natasha Slhessarenko, Francisco José Dutra Souto. (2008) Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine 26:8, 1032-1037
CrossRef181
Patrick Marcellin, Françoise Pequignot, Elisabeth Delarocque-Astagneau, Jean-Pierre Zarski, Nathalie Ganne, Patrick Hillon, Denise Antona, Martine Bovet, Murielle Mechain, Tarik Asselah, Jean-Claude Desenclos, Eric Jougla. (2008) Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. Journal of Hepatology 48:2, 200-207
CrossRef182
J.-F. Dufour. (2008) O tempora, o mores cancrorum. Liver International 28:2, 153-154
CrossRef183
Mario Rizzetto, Alessia Ciancio. (2008) Chronic HBV-related liver disease. Molecular Aspects of Medicine 29:1-2, 72-84
CrossRef184
Maureen M. Jonas. (2008) Treatment of chronic hepatitis B in children: Current status. Current Hepatitis Reports 7:1, 40-45
CrossRef185
A. Hoffmeister, I. Schiefke, N. Teich, J. Mössner, K. Schoppmeyer. (2008) Prävention von Malignomen des Verdauungstrakts. Der Internist 49:2, 178-184
CrossRef186
Ivan Borbath, Yves Horsmans. (2008) The Role of PPARγ in Hepatocellular Carcinoma. PPAR Research 2008, 1-4
CrossRef187
Hui-Chu Lang, Jaw-Ching Wu, Sang-Hue Yen, Chung-Fu Lan, Shi-Liang Wu. (2008) The Lifetime Cost of Hepatocellular Carcinoma. Applied Health Economics and Health Policy 6:1, 55-65
CrossRef188
Peter M. Howley, Joseph DeMasi. 2008. Infectious Agents and Cancer. , 67-89.
CrossRef189
Scott M. Lippman, J. Jack Lee. 2008. Cancer Chemoprevention. , 711-720.
CrossRef190
Erica Villa. (2008) Role of estrogen in liver cancer. Women's Health 4:1, 41-50
CrossRef191
Seunghee Jeong, Hyeon Woo Yim, Si Hyun Bae, WonChul Lee. (2008) Changes of Hepatitis B Surface Antigen Seroprevalence in Korea, 1998-2005. Korean Journal of Epidemiology 30:1, 119
CrossRef192
Biswajyoti Borkakoty, Jagadish Mahanta, Dipankar Biswas. (2007) HBV vaccination in hyperendemic remote tribal areas in India. Vaccine 25:50, 8347-8349
CrossRef193
Tung T. Nguyen, Vicky Taylor, Moon S. Chen, Roshan Bastani, Annette E. Maxwell, Stephen J. Mcphee. (2007) Hepatitis B awareness, knowledge, and screening among Asian Americans. Journal of Cancer Education 22:4, 266-272
CrossRef194
Chris Verslype, Louis Libbrecht. (2007) The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Practice & Research Clinical Gastroenterology 21:6, 983-996
CrossRef195
Heather F. Gidding, Margaret Warlow, C. Raina MacIntyre, Josephine Backhouse, Gwendolyn L. Gilbert, Helen E. Quinn, Peter B. McIntyre. (2007) The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 25:51, 8637-8641
CrossRef196
Ian H. Frazer, Doug R. Lowy, John T. Schiller. (2007) Prevention of cancer through immunization: Prospects and challenges for the 21st century. European Journal of Immunology 37:S1, S148-S155
CrossRef197
Fu-Hsiung Su, Shu-Hsing Cheng, Chung-Yi Li, Jong-Dar Chen, Chih-Yin Hsiao, Chih-Ching Chien, Ya-Chuan Yang, Hsiu-Hsing Hung, Fang-Yeh Chu. (2007) Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 25:47, 8085-8090
CrossRef198
Vijayakumar Velu, Subhadra Nandakumar, Saravanan Shanmugam, Esaki Muthu Shankar, Sundararajan Thangavel, Prasad Suryakant Kulkarni, Sadras Panchatcharam Thyagarajan. (2007) Comparative Efficacy of Two Dosages of Recombinant Hepatitis B Vaccine in Healthy Adolescents in India. The Pediatric Infectious Disease Journal 26:11, 1038-1041
CrossRef199
Ying Chun Shen, Chiun Hsu, Ann Lii Cheng. (2007) Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology 2:4, 199-210
CrossRef200
Sabrina Talukdar, C. Simon Herrington. 2007. Human DNA Tumour Viruses. .
CrossRef201
R. Iorio, A. Giannattasio, F. Cirillo, L. D'Alessandro, A. Vegnente. (2007) Long-Term Outcome in Children with Chronic Hepatitis B: A 24-Year Observation Period. Clinical Infectious Diseases 45:8, 943-949
CrossRef202
Li-Yu Wang, Hans Hsienhong Lin. (2007) Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 25:41, 7160-7167
CrossRef203
Janaki Amin, Dianne O'Connell, Mark Bartlett, Elizabeth Tracey, John Kaldor, Matthew Law, Gregory Dore. (2007) Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study. Australian and New Zealand Journal of Public Health 31:5, 475-482
CrossRef204
Melinda Sue YATES, Thomas Wells KENSLER. (2007) Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacologica Sinica 28:9, 1331-1342
CrossRef205
Junko Aono, Hiroshi Yotsuyanagi, Hideyuki Miyoshi, Takeya Tsutsumi, Hajime Fujie, Yoshizumi Shintani, Kyoji Moriya, Chiaki Okuse, Michihiro Suzuki, Kiyomi Yasuda, Shiro Iino, Kazuhiko Koike. (2007) Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis. Hepatology Research 37:9, 731-739
CrossRef206
Kwang-Hyub Han, Ja Kyung Kim. (2007) Liver cancer in Korea. Hepatology Research 37:s2 Fourth JSH S, S106-S109
CrossRef207
Ding-Shinn Chen. (2007) Hepatocellular carcinoma in Taiwan. Hepatology Research 37:s2 Fourth JSH S, S101-S105
CrossRef208
F.-H. Su, J.-D. Chen, S.-H. Cheng, K.-Y. Sung, J.-J. Jeng, F.-Y. Chu. (2007) Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18
years post-implementation of Taiwan?s national hepatitis B vaccination programme. Journal of Viral Hepatitis 0:0, 070901052026011-???
CrossRef209
C.-X. Qu, F. Kamangar, J.-H. Fan, B. Yu, X.-D. Sun, P. R. Taylor, B. E. Chen, C. C. Abnet, Y.-L. Qiao, S. D. Mark, S. M. Dawsey. (2007) Chemoprevention of Primary Liver Cancer: A Randomized, Double-Blind Trial in Linxian, China. JNCI Journal of the National Cancer Institute 99:16, 1240-1247
CrossRef210
Carlos Romero Marrero, Jorge A. Marrero. (2007) Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 38:6, 612-620
CrossRef211
Stephanie Roessler, Anuradha Budhu, Xin Wei Wang. (2007) Future of molecular profiling of human hepatocellular carcinoma. Future Oncology 3:4, 429-439
CrossRef212
Uchenna H. Iloeje, Hwai–I. Yang, Chin–Lan Jen, Jun Su, Li–Yu Wang, San–Lin You, Chien–Jen Chen. (2007) Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology 5:8, 921-931
CrossRef213
Rachel H. McMahan, Jill E. Slansky. (2007) Mobilizing the low-avidity T cell repertoire to kill tumors. Seminars in Cancer Biology 17:4, 317-329
CrossRef214
D. Koorey. (2007) Hepatocellular carcinoma: prevention, detection and treatment
CrossRef215
S.-W. Lai, W.-L. Chang, C.-Y. Peng, K.-F. Liao. (2007) Viral hepatitis among male amphetamine-inhaling abusers. Internal Medicine Journal 37:7, 472-477
CrossRef216
Robert G. Gish. (2007) Improving outcomes for patients with chronic hepatitis B. Hepatology Research 37:s1, S67-S78
CrossRef217
Geoffrey C Farrell, Neville D Yeomans. (2007) Emerging leaders of gastroenterology and hepatology in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 22:7, 961-962
CrossRef218
Mei-Hwei Chang. (2007) Hepatitis B virus infection. Seminars in Fetal and Neonatal Medicine 12:3, 160-167
CrossRef219
Li-Yu Wang, Hans Hsienhong Lin. (2007) Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Journal of Hepatology 46:6, 1018-1025
CrossRef220
Hashem B. El–Serag, K. Lenhard Rudolph. (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 132:7, 2557-2576
CrossRef221
Bryce Chackerian. (2007) Virus-like particles: flexible platforms for vaccine development. Expert Review of Vaccines 6:3, 381-390
CrossRef222
Fabien Zoulim. (2007) Emerging drugs for hepatitis B. Expert Opinion on Emerging Drugs 12:2, 199-217
CrossRef223
A DONOFRIO, P MANFREDI, E SALINELLI. (2007) Vaccinating behaviour, information, and the dynamics of SIR vaccine preventable diseases. Theoretical Population Biology 71:3, 301-317
CrossRef224
Jiunn-Jye Chuu, Jacqueline Ming Liu, Mei-Hua Tsou, Chen-Lung Huang, Ching-Ping Chen, Hsin-Sheng Wang, Chiung-Tong Chen. (2007) Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas. Journal of Biomedical Science 14:2, 233-244
CrossRef225
Yen–Hsuan Ni, Li–Min Huang, Mei–Hwei Chang, Chung–Jen Yen, Chun–Yi Lu, San–Lin You, Jia–Horng Kao, Yu–Chen Lin, Huey–Ling Chen, Hong–Yuan Hsu, Ding–Shinn Chen. (2007) Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies. Gastroenterology 132:4, 1287-1293
CrossRef226
Ping'an ZHU, Deming TAN, Zhongtian PENG, Fei LIU, Lin SONG. (2007) Polymorphism Analyses of Hepatitis B Virus X Gene in Hepatocellular Carcinoma Patients from Southern China. Acta Biochimica et Biophysica Sinica 39:4, 265-272
CrossRef227
Yun-Fan Liaw, Masao Omata, Shiv Kumar Sarin. (2007) Responding to the progress in hepatology: beyond the boundaries. Hepatology International 1:1, 1-2
CrossRef228
Robert G. Gish. (2007) Improving outcomes for patients with chronic hepatitis B. Current Gastroenterology Reports 9:1, 14-22
CrossRef229
Osman David Mansoor, Peter Salama. (2007) Should hepatitis B vaccine be used for infants?. Expert Review of Vaccines 6:1, 29-33
CrossRef230
Nermin N. Salkic, Muharem Zildzic, Kasim Muminhodzic, Nada Pavlovic-Calic, Enver Zerem, Sead Ahmetagic, Slavica Mott-Divkovic, Ervin Alibegovic. (2007) Intrafamilial transmission of hepatitis B in Tuzla region of Bosnia and Herzegovina. European Journal of Gastroenterology & Hepatology 19:2, 113-118
CrossRef231
W. Y. Lau, E. C. H. Lai. (2007) Liver surgery and transplantation in China: Progress and Challenges. Frontiers of Medicine in China 1:1, 1-5
CrossRef232
Fu-Hsiung Su, Jong-Dar Chen, Shu-Hsing Cheng, Ching-Hung Lin, Yi-Hui Liu, Fang-Yeh Chu. (2007) Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program. Journal of Medical Virology 79:2, 138-143
CrossRef233
Georgios Pappas, Photini Papadimitriou, Matthew E. Falagas. (2007) World Wide Web hepatitis B virus resources. Journal of Clinical Virology 38:2, 161-164
CrossRef234
Hiroaki Okuda. (2007) Hepatocellular carcinoma development in cirrhosis. Best Practice & Research Clinical Gastroenterology 21:1, 161-173
CrossRef235
Neung Hwa Park, Young-Hwa Chung. (2007) Molecular Mechanisms of Hepatitis B Virus-associated Hepatocellular Carcinoma. The Korean Journal of Hepatology 13:3, 320
CrossRef236
Frank Berthold, Uta Dirksen, Ulrich Gö Bel, Norbert Graf, Barbara Hero, Heribert Jü Rgens, Thomas Klingebiel, Ewa Koscielniak, Dietrich Von Schweinitz, Thorsten Simon, Regina Wieland, Johannes Wolff. 2007. Solide Tumoren. , 805-870.
CrossRef237
Vinod K Rustgi, Raymond S Koff. (2007) Future therapy for hepatitis B. Future Virology 2:1, 79-90
CrossRef238
Byung-Ho Choe. (2007) The management and treatment of chronic hepatitis B in Korean children. Korean Journal of Pediatrics 50:9, 823
CrossRef239
C.-C. Lin, C.-L. Chen, A. Concejero, C.-C. Wang, S.-H. Wang, Y.-W. Liu, C.-H. Yang, C.-C. Yong, T.-S. Lin, B. Jawan, Y.-F. Cheng, H.-L. Eng. (2007) Active Immunization to Prevent De Novo Hepatitis B Virus Infection in Pediatric Live Donor Liver Recipients. American Journal of Transplantation 7:1, 195-200
CrossRef240
Iain H. McKillop, Diarmuid M. Moran, Xiaoling Jin, Leonidas G. Koniaris. (2006) Molecular Pathogenesis of Hepatocellular Carcinoma. Journal of Surgical Research 136:1, 125-135
CrossRef241
Sheng-Nan Lu, Wei-Wen Su, Sheng-Shun Yang, Ting-Tsung Chang, Ken-Sheng Cheng, Jaw-Ching Wu, Hans Hsienhong Lin, Shun-Sheng Wu, Chuan-Mo Lee, Chi-Sin Changchien, Chien-Jen Chen, Jin-Chuan Sheu, Ding-Shinn Chen, Chien-Hung Chen. (2006) Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International Journal of Cancer 119:8, 1946-1952
CrossRef242
Voranush Chongsrisawat, Pornsak Yoocharoen, Apiradee Theamboonlers, Piyanit Tharmaphornpilas, Porpit Warinsathien, Supakarn Sinlaparatsamee, Siriraj Paupunwatana, Kasemporn Chaiear, Sawan Khwanjaipanich, Yong Poovorawan. (2006) Hepatitis B seroprevalence in Thailand: 12
CrossRef243
A FORNER. (2006) Hepatocarcinoma y VHC. Gastroenterología y Hepatología 29, 196-199
CrossRef244
L CASTELLSFUSTE. (2006) Virus de la hepatitis B y carcinoma hepatocelular. Gastroenterología y Hepatología 29, 86-92
CrossRef245
Mei-Hwei Chang. (2006) Hepatitis B virus mutation in children. The Indian Journal of Pediatrics 73:9, 803-807
CrossRef246
Bente Glintborg, Allan Weimann, Thomas W. Kensler, Henrik E. Poulsen. (2006) Oltipraz chemoprevention trial in Qidong, People's Republic of China: Unaltered oxidative biomarkers. Free Radical Biology and Medicine 41:6, 1010-1014
CrossRef247
Chien-Hung Chen, Ting-Tsung Chang, Ken-Sheng Cheng, Wei-Wen Su, Sheng-Shun Yang, Hans Hsienhong Lin, Shun-Sheng Wu, Chuan-Mo Lee, Chi-Sin Changchien, Chien-Jen Chen, Jin-Chuan Sheu, Ding-Shinn Chen, Sheng-Nan Lu. (2006) Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver International 26:7, 766-773
CrossRef248
Donald M. Parkin. (2006) The evolution of the population-based cancer registry. Nature Reviews Cancer 6:8, 603-612
CrossRef249
Chuan-Mo Lee, Sheng-Nan Lu, Chao-Hung Hung, Wei-Chih Tung, Jing-Houng Wang, Hung-Da Tung, Chien-Hung Chen, Tsung-Hui Hu, Chi-Sin Changchien, Wei-Jen Chen. (2006) Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Transactions of the Royal Society of Tropical Medicine and Hygiene 100:8, 767-774
CrossRef250
Maureen M. Jonas. (2006) Treatment of Chronic Hepatitis B in Children. Journal of Pediatric Gastroenterology and Nutrition 43:Supplement 1, S56-S60
CrossRef251
Siobhán M. O'Connor, Christopher E. Taylor, James M. Hughes. (2006) Emerging Infectious Determinants of Chronic Diseases. Emerging Infectious Diseases 12:7, 1051-1057
CrossRef252
Donald Maxwell Parkin. (2006) The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer 118:12, 3030-3044
CrossRef253
Sebastian Mueller, Nezam H. Afdhal, Detlef Schuppan. (2006) Iron, HCV, and Liver Cancer: Hard Metal Setting the Pace?. Gastroenterology 130:7, 2229-2234
CrossRef254
Mei-Hwei Chang. (2006) Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. Journal of Clinical Virology 36, S45-S50
CrossRef255
Andrew SH Lai, Kar Neng Lai. (2006) Viral nephropathy. Nature Clinical Practice Nephrology 2:5, 254-262
CrossRef256
Li-Yu Wang, Chi-Tan Hu, Tzu-Ying Ho, Hans Hsienhong Lin. (2006) Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. Vaccine 24:20, 4427-4432
CrossRef257
Arie J Zuckerman. 2006. Hepatitis Viruses. .
CrossRef258
Carlos Robles-Medranda, Hannah P. Lukashok, Paula Novais, Beatriz Biccas, Homero Foga??a. (2006) Chronic Diarrhea as First Manifestation of Liver Cirrhosis and Hepatocarcinoma in a Teenager. Journal of Pediatric Gastroenterology and Nutrition 42:4, 434-436
CrossRef259
Kuan-Fu Liao, Shih-Wei Lai, Wu-Long Chang, Nan-Yung Hsu. (2006) Screening for viral hepatitis among male non-drug-abuse prisoners. Scandinavian Journal of Gastroenterology1-1
CrossRef260
Maria V. Grau, Judy R. Rees, John A. Baron. (2006) Chemoprevention in Gastrointestinal Cancers: Current Status. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 281-287
CrossRef261
Andy S. Yu, Ramsey C. Cheung, Emmet B. Keeffe. (2006) Hepatitis B Vaccines. Infectious Disease Clinics of North America 20:1, 27-45
CrossRef262
C. John Clements, Yang Baoping, Alan Crouch, David Hipgrave, Osman Mansoor, Christopher B. Nelson, Sophie Treleaven, Ronald van Konkelenberg, Steven Wiersma. (2006) Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine 24:12, 1975-1982
CrossRef263
Paul H. Hayashi, Adrian M. Di Bisceglie. (2006) The Progression of Hepatitis B– and C–Infections to Chronic Liver Disease and Hepatocellular Carcinoma: Presentation, Diagnosis, Screening, Prevention, and Treatment of Hepatocellular Carcinoma. Infectious Disease Clinics of North America 20:1, 1-25
CrossRef264
G. C. Farrell, N. C. Teoh. (2006) Management of chronic hepatitis B virus infection: a new era of disease control. Internal Medicine Journal 36:2, 100-113
CrossRef265
Teresa L. Wright. (2006) Introduction to Chronic Hepatitis B Infection. The American Journal of Gastroenterology 101:S1, S1-S6
CrossRef266
D G Ward, Y Cheng, G N'kontchou, T T Thar, N Barget, W Wei, L J Billingham, A Martin, M Beaugrand, P J Johnson. (2006) Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. British Journal of Cancer 94:2, 287-292
CrossRef267
Lynne W Elmore, Xin Wei Wang, Curtis C Harris. 2006. Hepatocellular Carcinoma. .
CrossRef268
Rakesh Aggarwal, Shobna J Bhatia, Piyush Ranjan, Sanjeev Sachdev, Rakesh Aggarwal. 2006. Adefovir dipivoxil for chronic hepatitis B. .
CrossRef269
T. Hanslik, A.-J. Valleron, A. Flahault. (2006) Évaluer le rapport bénéfices/risques de la vaccination contre l'hépatite B en France en 2006. La Revue de Médecine Interne 27:1, 40-45
CrossRef270
Kazuo SHIRAKI. (2006) Infantile liver disease: Carry-over to the adult. 1. Carry-over of infantile viral hepatitis. Mainly on hepatitis B and hepatitis C.. Kanzo 47:2, 71-77
CrossRef271
Keith Nemergut, Edward C. Littlewood. 2006. Liver Diseases. , 151-201.
CrossRef272
Chuan-Mo Lee, Chao-Hung Hung, Sheng-Nan Lu, Jing-Houng Wang, Hung-Da Tung, Wu-Shiung Huang, Chao-Long Chen, Wei-Jen Chen, Chi-Sin Changchien. (2006) Viral Etiology of Hepatocellular Carcinoma and HCV Genotypes in Taiwan. Intervirology 49:1-2, 76-81
CrossRef273
Hiroshi Yoshizawa, Junko Tanaka, Yuzo Miyakawa. (2006) National Prevention of Hepatocellular Carcinoma in Japan Based on Epidemiology of Hepatitis C Virus Infection in the General Population. Intervirology 49:1-2, 7-17
CrossRef274
Dean M Robinson, Lesley J Scott, Greg L Plosker. (2006) Entecavir. Drugs 66:12, 1605-1622
CrossRef275
Graham A. Colditz, Thomas A. Sellers, Edward Trapido. (2006) Epidemiology — identifying the causes and preventability of cancer?. Nature Reviews Cancer 6:1, 75-83
CrossRef276
Hideo Yoshida, Haruhiko Yoshida, Shuichiro Shiina, Masao Omata. (2005) Early liver cancer: concepts, diagnosis, and management. International Journal of Clinical Oncology 10:6, 384-390
CrossRef277
Moon S. Chen. (2005) Cancer health disparities among Asian Americans. Cancer 104:S12, 2895-2902
CrossRef278
Alex Yui Hui, Joseph Jao-Yiu Sung. (2005) Advances in chronic viral hepatitis. Current Opinion in Internal Medicine 4:6, 548-554
CrossRef279
D. Lavanchy. (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of Clinical Virology 34, S1-S3
CrossRef280
Freda K Stevenson. (2005) Update on cancer vaccines. Current Opinion in Oncology 17:6, 573-577
CrossRef281
Alessandro Remo Zanetti, Andrea Mariano, Luisa Romanò, Raffaele D'Amelio, Maria Chironna, Rosa Cristina Coppola, Mario Cuccia, Rossana Mangione, Fosca Marrone, Francesco Saverio Negrone, Antonino Parlato, Emanuela Zamparo, Carla Zotti, Tommaso Stroffolini, Alfonso Mele. (2005) Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. The Lancet 366:9494, 1379-1384
CrossRef282
Jia-Horng Kao, Ding-Shinn Chen. (2005) Hepatitis B vaccination: to boost or not to boost?. The Lancet 366:9494, 1337-1338
CrossRef283
Mary F. Mulcahy. (2005) Management of hepatocellular cancer. Current Treatment Options in Oncology 6:5, 423-435
CrossRef284
Alex Yui Hui, Joseph Jao-Yiu Sung. (2005) Advances in chronic viral hepatitis. Current Opinion in Infectious Diseases 18:5, 400-406
CrossRef285
Eleftheria K. Zervou, Nikolaos K. Gatselis, Epthemia Xanthi, Kostas Ziciadis, Sarah P. Georgiadou, Georgios N. Dalekos. (2005) Intrafamilial spread of hepatitis B virus infection in Greece. European Journal of Gastroenterology & Hepatology 17:9, 911-915
CrossRef286
Stuart C. Gordon. (2005) Occult Viral Hepatitis and Noncirrhotic Hepatocellular Carcinoma. The American Journal of Gastroenterology 100:8, 1754-1757
CrossRef287
Jia-Horng Kao, Ding-Shinn Chen. (2005) Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver International 25:4, 696-703
CrossRef288
Yen-Hsuan Ni, Fu-Chen Huang, Tzee-Chung Wu, Man-Shan Kong, Yung-Ming Jeng, Pei-Jer Chen, Daw-Jen Tsuei, Huey-Ling Chen, Hong-Yuan Hsu, Mei-Hwei Chang. (2005) Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients. Pediatrics International 47:4, 372-377
CrossRef289
David FitzSimons, Guido François, Andrew Hall, Brian McMahon, André Meheus, Alessandro Zanetti, Bernard Duval, Wolfgang Jilg, Wulf Otto Böcher, Sheng-Nan Lu, Ulus Akarca, Daniel Lavanchy, Susan Goldstein, Jangu Banatvala, Pierre Van Damme. (2005) Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23:32, 4158-4166
CrossRef290
P D Griffiths. (2005) A shot in the arm for immunotherapy. Reviews in Medical Virology 15:4, 215-217
CrossRef291
F. Pappalardo, P.-L. Lollini, F. Castiglione, S. Motta. (2005) Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics 21:12, 2891-2897
CrossRef292
Darius Moradpour, Hubert E. Blum. (2005) Pathogenesis of hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 17:5, 477-483
CrossRef293
Mark Atkins, Marianne Nolan. (2005) Sexual transmission of hepatitis B. Current Opinion in Internal Medicine 4:2, 109-114
CrossRef294
CHYI-FENG JAN, CHIEN-JEN CHEN, HSIU-HSI CHEN. (2005) Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. Journal of Gastroenterology and Hepatology 20:4, 521-526
CrossRef295
Yi-Hsiang Huang, Jaw-Ching Wu, Chien-Hung Chen, Ting-Tsung Chang, Pui-Ching Lee, Gar-Yang Chau, Wing-Yiu Lui, Full-Young Chang, Shou-Dong Lee. (2005) Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver International 25:2, 236-241
CrossRef296
Paul H. Hayashi, Adrian M. Di Bisceglie. (2005) The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Medical Clinics of North America 89:2, 371-389
CrossRef297
Eldad Bialecki, Adrian Di Bisceglie. (2005) Diagnosis of hepatocellular carcinoma. HPB: Official Journal of The International Hepato Pancreato Biliary Association 7:1, 26-34
CrossRef298
Paul H. Hayashi, Adrian M. Di Bisceglie. (2005) The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America 89:2, 345-369
CrossRef299
J. J. Goedert. (2005) Preventing Infection-Associated Cancer: From Bench to Hillside. JNCI Journal of the National Cancer Institute 97:4, 245-246
CrossRef300
Mark Atkins, Marianne Nolan. (2005) Sexual transmission of hepatitis B. Current Opinion in Infectious Diseases 18:1, 67-72
CrossRef301
Hubert E. Blum. (2005) Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 19:1, 129-145
CrossRef302
Steven F Moss, Martin J Blaser. (2005) Mechanisms of Disease: inflammation and the origins of cancer. Nature Clinical Practice Oncology 2:2, 90-97
CrossRef303
Katherine A. McGlynn, W.Thomas London. (2005) Epidemiology and natural history of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 19:1, 3-23
CrossRef304
(2005) Hepatitis B Virus. Transfusion Medicine and Hemotherapy 32:3-4, 151-159
CrossRef305
S. Chaudhuri, S. Das, A. Chowdhury, A. Santra, S.K. Bhattacharya, T.N. Naik. (2005) Molecular epidemiology of HCV infection among acute and chronic liver disease patients in Kolkata, India. Journal of Clinical Virology 32:1, 38-46
CrossRef306
Poland, Gregory A., Jacobson, Robert M., . (2004) Prevention of Hepatitis B with the Hepatitis B Vaccine. New England Journal of Medicine 351:27, 2832-2838
Full Text307
Chun-Yi Lu, Bor-Luen Chiang, Wei-Kuang Chi, Mei-Hwei Chang, Yen-Hsuan Ni, Hsu-Mei Hsu, Shiing-Jer Twu, Ih-Jen Su, Li-Min Huang, Chin-Yun Lee. (2004) Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40:6, 1415-1420
CrossRef308
Josep M. Llovet. (2004) Treatment of hepatocellular carcinoma. Current Treatment Options in Gastroenterology 7:6, 431-441
CrossRef309
Sonia R. Pagliusi, M. Teresa Aguado. (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:5, 569-578
CrossRef310
Tarik Asselah, Corinne Castelnau, Nathalie Boyer, Marie-Pierre Ripault, Patrick Marcellin. (2004) Traitement de l’hépatite chronique B. Gastroentérologie Clinique et Biologique 28:12, 1215-1227
CrossRef311
Joseph S. Pagano, Martin Blaser, Marie-Annick Buendia, Blossom Damania, Kamel Khalili, Nancy Raab-Traub, Bernard Roizman. (2004) Infectious agents and cancer: criteria for a causal relation. Seminars in Cancer Biology 14:6, 453-471
CrossRef312
Daniel H Palmer, Syed A Hussain, Philip J Johnson. (2004) Systemic therapies for hepatocellular carcinoma. Expert Opinion on Investigational Drugs 13:12, 1555-1568
CrossRef313
Ian Frazer. (2004) Is vaccine therapy the future in cancer prevention?. Expert Opinion on Pharmacotherapy 5:12, 2427-2434
CrossRef314
Arun Chakrabarty, Karl Beutner. (2004) Therapy of other viral infections: herpes to hepatitis. Dermatologic Therapy 17:6, 465-490
CrossRef315
Man-Fung Yuen, Ching-Lung Lai. (2004) Treatment for Hepatitis B. Journal of Clinical Gastroenterology 38, S134-S135
CrossRef316
Anna S.F. Lok. (2004) Prevention of hepatitis B virus–related hepatocellular carcinoma. Gastroenterology 127:5, S303-S309
CrossRef317
Jay H. Hoofnagle. (2004) Hepatocellular carcinoma: Summary and recommendations. Gastroenterology 127:5, S319-S323
CrossRef318
F.Xavier Bosch, Josepa Ribes, Mireia Díaz, Ramon Cléries. (2004) Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:5, S5-S16
CrossRef319
Thomas W. Kensler, Patricia A. Egner, Jin-Bing Wang, Yuan-Rong Zhu, Bao-Chu Zhang, Pei-Xin Lu, Jian-Guo Chen, Geng-Sun Qian, Shuang-Yuan Kuang, Peta E. Jackson, Stephen J. Gange, Lisa P. Jacobson, Alvaro Muñoz, John D. Groopman. (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127:5, S310-S318
CrossRef320
Chee-Ruey Hsieh, Chuei-Wen Kuo. (2004) Cost of Chronic Hepatitis B Virus Infection in Taiwan. Journal of Clinical Gastroenterology 38, S148-S152
CrossRef321
Wands, Jack R., . (2004) Prevention of Hepatocellular Carcinoma. New England Journal of Medicine 351:15, 1567-1570
Full Text322
M. Anzola. (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. Journal of Viral Hepatitis 11:5, 383-393
CrossRef323
Cindy J. Lai, Norah A. Terrault. (2004) Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterology Clinics of North America 33:3, 629-654
CrossRef324
Josepa Ribes, Ramon Cl??ries, Joan Borr??s, Jaume Galceran, F Xavier Bosch. (2004) Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980???1997 in Catalonia, Spain. European Journal of Gastroenterology & Hepatology 16:9, 865-872
CrossRef325
EVE A. ROBERTS. (2004) Hepatitis B: The Next Generation. Pediatric Research 56:3, 318-320
CrossRef326
FT Cutts, AJ Hall. (2004) Vaccines for neonatal viral infections: Hepatitis B vaccine. Expert Review of Vaccines 3:4, 349-352
CrossRef327
J Maher, E T Davies. (2004) Targeting cytotoxic T lymphocytes for cancer immunotherapy. British Journal of Cancer
CrossRef328
Beatrice Gerard, Harry Bleiberg. (2004) Treatment of hepatocarcinoma. Current Oncology Reports 6:3, 184-191
CrossRef329
Mei-Hwei Chang, Dino Hadzic, Solange Heller Rouassant, Maureen Jonas, I. Joaquin Kohn, Francesco Negro, Eve Roberts, Anupam Sibal. (2004) Acute and Chronic Hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition 39, S584-S588
CrossRef330
Alfredo Alberti, Giovanna Fattovich. (2004) Natural history of chronic hepatitis B. Current Hepatitis Reports 3:2, 54-60
CrossRef331
T. Muñoz Yagüe. (2004) Tumores hepáticos. Medicine - Programa de Formación Médica Continuada Acreditado 9:10, 595-605
CrossRef332
Tran T T Huy, Kenji Abe. (2004) Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatrics International 46:2, 223-230
CrossRef333
Charmaine Venters, William Graham, William Cassidy. (2004) Recombivax-HB: perspectives past, present and future. Expert Review of Vaccines 3:2, 119-129
CrossRef334
Christoph E Broelsch, Andrea Frilling, Massimo Malago. (2004) Hepatoma—resection or transplantation. Surgical Clinics of North America 84:2, 495-511
CrossRef335
Chengbin Wang, Jianming Tang, Wei Song, Elena Lobashevsky, Craig M. Wilson, Richard A. Kaslow. (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39:4, 978-988
CrossRef336
Linda L Wong, Naoky Tsai, Whitney Limm, Livingston Wong. (2004) Liver transplant for hepatocellular cancer: a treatment for the select few. Clinical Transplantation 18:2, 205-210
CrossRef337
Thomas R. OʼBrien, Gregory Kirk, Mingdong Zhang. (2004) Hepatocellular Carcinoma. The Cancer Journal 10:2, 67-73
CrossRef338
Jordi Bruix, Loreto Boix, Margarita Sala, Josep M Llovet. (2004) Focus on hepatocellular carcinoma. Cancer Cell 5:3, 215-219
CrossRef339
D. Lavanchy. (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11:2, 97-107
CrossRef340
Sylvie Ranger-Rogez, Fran¸ois Denis. (2004) Hepatitis B mother-to-child transmission. Expert Review of Anti-infective Therapy 2:1, 133-145
CrossRef341
CHO-YU CHAN, SHOU-DONG LEE, KWANG-JUEI LO. (2004) Legend of hepatitis B vaccination: The Taiwan experience. Journal of Gastroenterology and Hepatology 19:2, 121-126
CrossRef342
Masao Omata, Haruhiko Yoshida. (2004) Prevention and treatment of hepatocellular carcinoma. Liver Transplantation 10:S2, S111-S114
CrossRef343
Laurie Blendis, Morris Sherman. (2004) Hepatocellular Carcinoma. American Journal of Cancer 3:6, 349-368
CrossRef344
Huey-Ling Chen, Chee-Jen Chang, Man-Shan Kong, Fu-Chen Huang, Hung-Chang Lee, Chieh-Chung Lin, Ching-Chuan Liu, I-Hsien Lee, Tzee-Chung Wu, Shu-Fen Wu, Yen-Hsuan Ni, Hong-Yuan Hsu, Ding-Shinn Chen, Mei-Hwei Chang. (2004) Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 39:1, 58-63
CrossRef345
Francis A Waldvogel. (2004) Infectious diseases in the 21st century: old challenges and new opportunities. International Journal of Infectious Diseases 8:1, 5-12
CrossRef346
Shelly Beer, Anders Zetterberg, Rebecca A. Ihrie, Ryan A. McTaggart, Qiwei Yang, Nicole Bradon, Constadina Arvanitis, Laura D. Attardi, Sandy Feng, Boris Ruebner, Robert D. Cardiff, Dean W. Felsher. (2004) Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biology 2:11, e332
CrossRef347
Will J. Fecht, Alex S. Befeler. (2004) Hepatocellular carcinoma: Updates in primary prevention. Current Gastroenterology Reports 6:1, 37-43
CrossRef348
Akihiro Tamori, Shuhei Nishiguchi, Shoji Kubo, Takashi Narimatsu, Daiki Habu, Tadashi Takeda, Kazuhiro Hirohashi, Susumu Shiomi. (2003) HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. Journal of Medical Virology 71:4, 492-498
CrossRef349
Josep M Llovet, Andrew Burroughs, Jordi Bruix. (2003) Hepatocellular carcinoma. The Lancet 362:9399, 1907-1917
CrossRef350
Ching Lung Lai, Vlad Ratziu, Man-Fung Yuen, Thierry Poynard. (2003) Viral hepatitis B. The Lancet 362:9401, 2089-2094
CrossRef351
BIAO XU, DE-CHANG HU, DANIEL M ROSENBERG, QING-WU JIANG, XI-MIN LIN, JIA-LIANG LU, NOAH J ROBINSON. (2003) Chronic hepatitis B: A long-term retrospective cohort study of disease progression in Shanghai, China. Journal of Gastroenterology and Hepatology 18:12, 1345-1352
CrossRef352
Freda K Stevenson, Andrew King, Christian H Ottensmeier. (2003) Vaccine Therapy in NHL: Future Promises and Current Limitations. Leukemia & Lymphoma 44:S3, S85-S90
CrossRef353
Kendal Yalcin, Ramazan Danis, Halil Degertekin, M. Nail Alp, Selahattin Tekes, Turgay Budak. (2003) The Lack of Effect of Therapeutic Vaccination With a Pre-S2/S HBV Vaccine in the Immune Tolerant Phase of Chronic HBV Infection. Journal of Clinical Gastroenterology 37:4, 330-335
CrossRef354
Mei-Hwei Chang. (2003) Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver International 23:5, 309-314
CrossRef355
HIROSHI NOTO, TOSHIHIKO TERAO, SHIGEO RYOU, YASUYUKI HIROSE, TAKAMI YOSHIDA, HIDEO OOKUBO, HIDETOSHI MITO, HIROSHI YOSHIZAWA, . (2003) Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980-1994. Journal of Gastroenterology and Hepatology 18:8, 943-949
CrossRef356
YAO-JONG YANG, CHING-CHUAN LIU, TE-JEN CHEN, MENG-FENG LEE, SHENG-HSIEN CHEN, HSIANG-HUNG SHIH, MEI-HWEI CHANG. (2003) Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. The Pediatric Infectious Disease Journal 22:7, 584-588
CrossRef357
G. Ada. (2003) Progress towards achieving new vaccine and vaccination goals. Internal Medicine Journal 33:7, 297-304
CrossRef358
Kathleen B. Schwarz. (2003) Pediatric issues in new therapies for hepatitis B and C. Current Gastroenterology Reports 5:3, 233-239
CrossRef359
Javier Arístegui, Vytautas Usonis, Hoosen Coovadia, Stella Riedemann, Khin Maung Win, Salvacion Gatchalian, Hans L. Bock. (2003) Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. International Journal of Infectious Diseases 7:2, 143-151
CrossRef360
Sheng-Nan Lu, Tsung-Ming Chen, Chuan-Mo Lee, Jing-Houng Wang, Hung-Da Tung, Jaw-Ching Wu. (2003) Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. Journal of Medical Virology 70:1, 74-80
CrossRef361
Philippe Duclos. (2003) Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opinion on Drug Safety 2:3, 225-231
CrossRef362
Glenn Dranoff. (2003) Coordinated tumor immunity. Journal of Clinical Investigation 111:8, 1116-1118
CrossRef363
Julian Katz, James C Reynolds. (2003) The early diagnosis and prevention of gastrointestinal cancer: problems and promises. Hematology/Oncology Clinics of North America 17:2, 351-360
CrossRef364
Hans Hsienhong Lin, Li-Yu Wang, Chi-Tan Hu, Shih-Che Huang, Lu-Chin Huang, Sherry S.J. Lin, Yu-Ming Chiang, Tso-Tsai Liu, Chien-Lin Chen. (2003) Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: Sixteen years after newborn vaccination program in Taiwan. Journal of Medical Virology 69:4, 471-474
CrossRef365
Akihiro Tamori, Shuhei Nishiguchi, Shoji Kubo, Masaru Enomoto, Noritoshi Koh, Tadashi Takeda, Susumu Shiomi, Kazuhiro Hirohashi, Hiroaki Kinoshita, Shuzo Otani. (2003) Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. Journal of Medical Virology 69:4, 475-481
CrossRef366
Ho-Hsiung Lin, Jia-Horng Kao, Ting-Chen Chang, Hong-Yuan Hsu, Ding-Shinn Chen. (2003) Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. Journal of Medical Virology 69:4, 466-470
CrossRef367
Joseph B. Miller. (2003) Successful Immunotherapy of Acute Viral Infections with a Virus Vaccine. Journal of Nutritional and Environmental Medicine 13:1, 31-47
CrossRef368
B. W. Y. Young, S. S. Lee, W. L. Lim, E. K. Yeoh. (2003) The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. Journal of Viral Hepatitis 10:1, 23-30
CrossRef369
Chandan Guha, Shalin J. Shah, Siddhartha S. Ghosh, Sung W. Lee, Namita Roy-Chowdhury, Jayanta Roy-Chowdhury. (2003) Molecular Therapies for Viral Hepatitis. BioDrugs 17:2, 81-91
CrossRef370
PAUL C TURNER, ABDOULAYE SYLLA, MAMADOU S DIALLO, JEAN-JACQUES CASTEGNARO, ANDREW J HALL, CHRISTOPHER P WILD. (2002) The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. Journal of Gastroenterology and Hepatology 17:s4, S441-S448
CrossRef371
HUBERT E BLUM, DARIUS MORADPOUR. (2002) Antiviral treatment of patients with HBV-related cirrhosis. Journal of Gastroenterology and Hepatology 17:s3, S306-S310
CrossRef372
HUBERT E BLUM, DARIUS MORADPOUR. (2002) Viral pathogenesis of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 17:s3, S413-S420
CrossRef373
Yaw-Sen Chen, Chih-Chi Wang, Vanessa H de Villa, Shih-Hor Wang, Yu-Fan Cheng, Tung-Liang Huang, Bruno Jawan, King-Wah Chiu, Chao-Long Chen. (2002) Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clinical Transplantation 16:6, 405-409
CrossRef374
Daw-Jen Tsuei, Mei-Hwei Chang, Pei-Jer Chen, Tsuey-Ying Hsu, Yen-Hsuan Ni. (2002) Characterization of integration patterns and flanking cellular sequences of hepatitis B virus in childhood hepatocellular carcinomas. Journal of Medical Virology 68:4, 513-521
CrossRef375
Michael C Kew. (2002) Epidemiology of hepatocellular carcinoma. Toxicology 181-182, 35-38
CrossRef376
Thomas G Evans, Muhammad Hasan, Laurent Galibert, Dania Caron. (2002) The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. Vaccine 21:3-4, 322-329
CrossRef377
Charles Stiller. (2002) Epidemiology of cancer in adolescents. Medical and Pediatric Oncology 39:3, 149-155
CrossRef378
K. Okuda. (2002) Hepatocellular carcinoma — History, current status and perspectives. Digestive and Liver Disease 34:9, 613-616
CrossRef379
A DIBISCEGLIE. (2002) Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 13:9, S169-S171
CrossRef380
A KOTEISH, P THULUVATH. (2002) Screening for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 13:9, S185-S190
CrossRef381
Hans Hsienhong Lin, Sherry S.J. Lin, Yu-Ming Chiang, Li-Yu Wang, Lu-Chin Huang, Shi-Che Huang, Tso-Tsa Liu. (2002) Trend of hepatitis B virus infection in freshmen classes at two high schools in Hualien, Taiwan from 1991 to 1999. Journal of Medical Virology 67:4, 472-476
CrossRef382
Liang, T. Jake, Ghany, Marc, . (2002) Hepatitis B e Antigen — The Dangerous Endgame of Hepatitis B. New England Journal of Medicine 347:3, 208-210
Full Text383
Mario Rizzetto, Alessandro R. Zanetti. (2002) Progress in the prevention and control of viral hepatitis type B: Closing remarks. Journal of Medical Virology 67:3, 463-466
CrossRef384
Alfredo Alberti, Maurizia Rossana Brunetto, Massimo Colombo, Antonio Crax
CrossRef385
Pierre Van Damme, Alex Vorsters. (2002) Hepatitis B control in Europe by universal vaccination programmes: The situation in 2001. Journal of Medical Virology 67:3, 433-439
CrossRef386
Alexander Milne, David J. West, Dang Van Chinh, Chris D. Moyes, Gabriele Poerschke. (2002) Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. Journal of Medical Virology 67:3, 327-333
CrossRef387
Ruggero Montesano. (2002) Hepatitis B immunization and hepatocellular carcinoma: The Gambia hepatitis Intervention Study. Journal of Medical Virology 67:3, 444-446
CrossRef388
Kathleen B. Schwarz, William Balistreri. (2002) Viral Hepatitis. Journal of Pediatric Gastroenterology and Nutrition 35, S29-S32
CrossRef389
Julian Katz, James C Reynolds. (2002) The early diagnosis and prevention of gastrointestinal cancer: problems and promises. Gastroenterology Clinics of North America 31:2, 369-378
CrossRef390
GIUSEPPE MONTALTO, MELCHIORRE CERVELLO, LYDIA GIANNITRAPANI, FABIO DANTONA, ANGELA TERRANOVA, LUIGI A. M. CASTAGNETTA. (2002) Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma. Annals of the New York Academy of Sciences 963:1, 13-20
CrossRef391
Ivan Borrello, Drew Pardoll. (2002) GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine & Growth Factor Reviews 13:2, 185-193
CrossRef392
Glenn Dranoff. (2002) Immune recognition and tumor protection. Current Opinion in Immunology 14:2, 161-164
CrossRef393
Shruti H Mehta, Andrea Cox, Donald R Hoover, Xiao-Hong Wang, Qing Mao, Stuart Ray, Steffanie A Strathdee, David Vlahov, David L Thomas. (2002) Protection against persistence of hepatitis C. The Lancet 359:9316, 1478-1483
CrossRef394
Etienne Sokal. (2002) Lamivudine for the treatment of chronic hepatitis B. Expert Opinion on Pharmacotherapy 3:3, 329-339
CrossRef395
Nguyen Trong Hieu, Kyung-Ho Kim, Zbigniew Janowicz, Ivo Timmermans. (2002) Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 20:13-14, 1803-1808
CrossRef396
Blake Cady. (2002) Breast cancer: An introduction to the problem. Obstetrics and Gynecology Clinics of North America 29:1, 117-122
CrossRef397
YONG POOVORAWAN, PANTIPA CHATCHATEE, VORANUSH CHONGSRISAWAT. (2002) Epidemiology and prophylaxis of viral hepatitis:A global perspective. Journal of Gastroenterology and Hepatology 17, S155-S166
CrossRef398
James S. Edstam, Nyamkhuu Dulmaa, Pagbajabyn Nymadawa, Arslan Rinchin, J. Khulan, Ann Marie Kimball. (2002) Comparison of Hepatitis B Vaccine Coverage and Effectiveness among Urban and Rural Mongolian 2-Year-Olds. Preventive Medicine 34:2, 207-214
CrossRef399
C.-J. Chen. (2002) Cancer Epidemiology and Control in Taiwan: a Brief Review. Japanese Journal of Clinical Oncology 32:90001, 66S-81
CrossRef400
Jia-Horng Kao, Ding-Shinn Chen. (2002) Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. International Journal of Cancer 97:3, 269-271
CrossRef401
Etienne Sokal. (2002) Drug Treatment of Pediatric Chronic Hepatitis B. Pediatric Drugs 4:6, 361-369
CrossRef402
Paul R. Engstrom. 2002. Hepatocellular Carcinoma (HCC). , 363-371.
CrossRef403
Delin Zhu, Jason Rice, Natalia Savelyeva, Freda K Stevenson. (2001) DNA fusion vaccines against B-cell tumors. Trends in Molecular Medicine 7:12, 566-572
CrossRef404
Masataka Okuno, Soichi Kojima, Hisataka Moriwaki. (2001) Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives. Journal of Gastroenterology and Hepatology 16:12, 1329-1335
CrossRef405
Philippe Beutels. (2001) Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Economics 10:8, 751-774
CrossRef406
P. Moingeon. (2001) Cancer vaccines. Vaccine 19:11-12, 1305-1326
CrossRef407
Stanley A. Plotkin. (2001) John Snow learns from Louis Pasteur. The Pediatric Infectious Disease Journal 20:11, 1073-1078
CrossRef408
Katherine A. McGlynn, Lilian Tsao, Ann W. Hsing, Susan S. Devesa, Joseph F. Fraumeni. (2001) International trends and patterns of primary liver cancer. International Journal of Cancer 94:2, 290-296
CrossRef409
Mackay, Ian R., Rosen, Fred S., , Ada, Gordon, . (2001) Vaccines and Vaccination. New England Journal of Medicine 345:14, 1042-1053
Full Text410
P P Anthony. (2001) Hepatocellular carcinoma: an overview. Histopathology 39:2, 109-118
CrossRef411
M.A. Epstein. (2001) Reflections on Epstein–Barr Virus: Some Recently Resolved Old Uncertainties. Journal of Infection 43:2, 111-115
CrossRef412
Blake Cady. (2001) Breast cancer in the third millennium. Journal of Surgical Oncology 77:4, 225-232
CrossRef413
Yasushi Shiratori, Haruhiko Yoshida, Masao Omata. (2001) Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Review of Anticancer Therapy 1:2, 277-290
CrossRef414
Khomotso V Tsebe, Rosemary J Burnett, Nyiko P Hlungwani, Mbudzeni M Sibara, Philip A Venter, M.Jeffrey Mphahlele. (2001) The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 19:28-29, 3919-3926
CrossRef415
K.S. Chia, W.B. Du, R. Sankaranarayanan, R. Sankila, A. Seow, H.P. Lee. (2001) Population-based cancer survival in Singapore, 1968 to 1992: An overview. International Journal of Cancer 93:1, 142-147
CrossRef416
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, B. K. Edwards. (2001) Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends. JNCI Journal of the National Cancer Institute 93:11, 824-842
CrossRef417
Anna S. Lok, E. Jenny Heathcote, Jay H. Hoofnagle. (2001) Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology 120:7, 1828-1853
CrossRef418
Blake Cady. (2001) Fundamentals of contemporary surgical oncology: biologic principles and the threshold concept govern treatment and outcomes1 1No competing interests declared.. Journal of the American College of Surgeons 192:6, 777-792
CrossRef419
Shih-Min Wang, Ching-Chuan Liu, Yi-Shen Huang, Yao-Jong Yang, Huan-Yao Lei. (2001) Change in hepatitis A virus seroepidemiology in southern Taiwan: a large percentage of the population lack protective antibody. Journal of Medical Virology 64:2, 104-108
CrossRef420
E Lazcano-Ponce. (2001) Acceptability of a Human Papillomavirus (HPV) Trial Vaccine Among Mothers of Adolescents in Cuernavaca, Mexico. Archives of Medical Research 32:3, 243-247
CrossRef421
Michael P. Cooreman, Geert Leroux-Roels, Wilma P. Paulij. (2001) Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. Journal of Biomedical Science 8:3, 237-247
CrossRef422
Manish M. Chokshi, Jorge A. Marrero. (2001) Hepatocellular carcinoma. Current Opinion in Gastroenterology 17:3, 276-280
CrossRef423
Hsu-Mei Hsu, Shin-Chwen Lee, Ming-Ching Wang, Szu-Fong Lin, Ding-Shinn Chen. (2001) Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. Vaccine 19:20-22, 2825-2829
CrossRef424
Patrick Arbuthnot, Michael Kew. (2001) Hepatitis B virus and hepatocellular carcinoma. International Journal of Experimental Pathology 82:2, 77-100
CrossRef425
Toby Coates, Rosamund Wilson, Guy Patrick, Francis André, Virginia Watson. (2001) Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clinical Therapeutics 23:3, 392-403
CrossRef426
Alessandro R Zanetti. (2001) Update on hepatitis B vaccination in Italy 10 years after its implementation. Vaccine 19:17-19, 2380-2383
CrossRef427
Raymond S. Koff. (2001) Hepatitis Vaccines. Infectious Disease Clinics of North America 15:1, 83-95
CrossRef428
Pierre Van Damme. (2001) Hepatitis B: vaccination programmes in Europe — an update. Vaccine 19:17-19, 2375-2379
CrossRef429
A. S. Fauci. (2001) Infectious Diseases: Considerations for the 21st Century. Clinical Infectious Diseases 32:5, 675-685
CrossRef430
C. D. Harro, Y.-Y. S. Pang, R. B. S. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, D. R. Lowy. (2001) Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine. JNCI Journal of the National Cancer Institute 93:4, 284-292
CrossRef431
F. K. Stevenson, W. Rosenberg. (2001) DNA vaccination: a potential weapon against infection and cancer. Vox Sanguinis 80:1, 12-18
CrossRef432
Christopher N. H. Jenkins, Chau Buu, Wendy Berger, Do T. Son. (2001) Liver carcinoma prevention among Asian Pacific Islanders. Cancer 91:S1, 252-256
CrossRef433
Yong Poovorawan, Apiradee Theamboonlers, Thosporn Vimolket, Supakarn Sinlaparatsamee, Kasemporn Chaiear, Taweesap Siraprapasiri, Sawan Khwanjaipanich, Somchai Owatanapanich, Petra Hirsch, Supamit Chunsuttiwat. (2000) Impact of hepatitis B immunisation as part of the EPI. Vaccine 19:7-8, 943-949
CrossRef434
Gregory T. Everson. (2000) Increasing incidence and pretransplantation screening of hepatocellular carcinoma. Liver Transplantation 6:6B, s2-s10
CrossRef435
Shou-Dong Lee. (2000) Asian perspectives on viral hepatitis A. Journal of Gastroenterology and Hepatology 15:s3, G94-G99
CrossRef436
Blake Cady. (2000) Breast Cancer in the Third Millennium. The Breast Journal 6:5, 280-287
CrossRef437
Philip J. Johnson. (2000) Systemic chemotherapy of liver tumors. Seminars in Surgical Oncology 19:2, 116-124
CrossRef438
Hugo R. Rosen, Paul Martin. (2000) VIRAL HEPATITIS IN THE LIVER TRANSPLANT RECIPIENT. Infectious Disease Clinics of North America 14:3, 761-784
CrossRef439
Rebecca L Jones, Lawrence S Young, David H Adams. (2000) Immunotherapy in hepatocellular carcinoma. The Lancet 356:9232, 784-785
CrossRef440
(2000) Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region1 . CORE WORKING PARTY FOR ASIA-PACIFIC CONSENSUS ONHEPATITIS B AND C2. Journal of Gastroenterology and Hepatology 15:8, 825-839
CrossRef441
RUTH L MALCOLM, LOCKLEN LUDWICK, DIANNE L BROOKES, JEFFREY N HANNA. (2000) The investigation of a ‘cluster’ of hepatitis B in teenagers from an Indigenous community in North Queensland. Australian and New Zealand Journal of Public Health 24:4, 353-355
CrossRef442
Mei-Hwei Chang. (2000) Hepatitis B Vaccination and Control of Hepatitis B???Related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition 31:2, 112-117
CrossRef443
Willis C. Maddrey. (2000) Hepatitis B: An important public health issue. Journal of Medical Virology 61:3, 362-366
CrossRef444
Andrew D. Murdin, Bruce Gellin, Robert C. Brunham, Lee Ann Campbell, Gunna Christiansen, Carolyn D. Deal, Hal B. Jenson, Benjamin Metcalf, Banu Sankaran, Richard S. Stephens, Cathy Wilfert. (2000) Collaborative Multidisciplinary Workshop Report: Progress toward a Chlamydia pneumoniae Vaccine. The Journal of Infectious Diseases 181:s3, S552-S557
CrossRef445
Geoffrey C Farrell, Yun-Fan Liaw. (2000) Towards consensus on the control of chronic hepatitis B and hepatitis C in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E1-E2
CrossRef446
Mei-Hwei Chang. (2000) Natural history of hepatitis B virus infection in children. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E16-E19
CrossRef447
Kazuo Shiraki. (2000) Perinatal transmission of hepatitis B virus and its prevention. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E11-E15
CrossRef448
Philip S. Rice, Christine Mant, John Cason, Jon M. Bible, Peter Muir, Barbara Kell, Jennifer M. Best. (2000) High prevalence of human papillomavirus type 16 infection among children. Journal of Medical Virology 61:1, 70-75
CrossRef449
Chien-Jen Chen, Li-Yu Wang, Ming-Whei Yu. (2000) Epidemiology of hepatitis B virus infection in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E3-E6
CrossRef450
John T. Edwards, Graeme A. Macdonald. (2000) Hepatocellular carcinoma. Current Opinion in Gastroenterology 16:3, 275-281
CrossRef451
Ding-Shinn Chen. (2000) Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E7-E10
CrossRef452
Philippe Monteyne, Francis E André. (2000) Is there a causal link between hepatitis B vaccination and multiple sclerosis?. Vaccine 18:19, 1994-2001
CrossRef453
Assad Safary, Janice Beck. (2000) Vaccination against hepatitis B: Current challenges for Asian countries and future directions. Journal of Gastroenterology and Hepatology 15:4, 396-401
CrossRef454
Christopher P. Wild, Andrew J. Hall. (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutation Research/Reviews in Mutation Research 462:2-3, 381-393
CrossRef455
Kun-Yen Huang, Sheue-Rong Lin. (2000) Nationwide vaccination: A success story in Taiwan. Vaccine 18, S35-S38
CrossRef456
Francis André. (2000) Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18, S20-S22
CrossRef457
Luis M. Montuenga, James L. Mulshine. (2000) New Molecular Strategies for Early Lung Cancer Detection. Cancer Investigation 18:6, 555-563
CrossRef458
H zurHausen. (1999) Viruses in human cancers. European Journal of Cancer 35:14, 1878-1885
CrossRef459
Mei-Hwei Chang, Ding-Shinn Chen. (1999) Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 13:4, 511-517
CrossRef460
Fabien Zoulim. (1999) Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Research 44:1, 1-30
CrossRef461
Etienne M. Sokal, Flavia Bortolotti. (1999) Update on prevention and treatment of viral hepatitis in children. Current Opinion in Pediatrics 11:5, 384-389
CrossRef462
Chuan-Mo Lee, Sheng-Nan Lu, Chi-Sin Changchien, Chau-Ting Yeh, Tsung-Teng Hsu, Jui-Hsiang Tang, Jing-Houng Wang, Deng-Yn Lin, Chao-Long Chen, Wei-Jen Chen. (1999) Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 86:7, 1143-1150
CrossRef463
Jiing-Chyuan Luo, Shinn-Jang Hwang, Jaw-Ching Wu, Chung-Pin Li, Linag-Tsai Hsiao, Chiung-Ru Lai, Jen-Huei Chiang, Wing-Yiu Lui, Full-Young Chang, Shou-Dong Lee. (1999) Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. Cancer 86:5, 799-804
CrossRef464
Robert C. Kurtz. (1999) Hepatocellular carcinoma and coinfection with hepatitis B and C. Cancer 86:5, 741-743
CrossRef465
S. Viviani, A. Jack, A.J. Hall, N. Maine, M. Mendy, R. Montesano, H.C. Whittle. (1999) Hepatitis B vaccination in infancy in The Gambia: protection. Vaccine 17:23-24, 2946-2950
CrossRef466
F. Klotz, J. M. Debonne, M. Richecœur. (1999) L’hépatocarcinome sous les tropiques. Acta Endoscopica 29:4, 445-451
CrossRef467
Abdoulaye Sylla, Mamadou Samba Diallo, Jean-Jacques Castegnaro, Christopher Paul Wild. (1999) Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 428:1-2, 187-196
CrossRef468
S. Zhong, J. Y. H. Chan, W. Yeo, J. S. Tam, P. J. Johnson. (1999) Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. Journal of Viral Hepatitis 6:3, 195-202
CrossRef469
Jia-Horng Kao, Michael Wood, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen. (1999) Comparison of two methods for quantification of hepatitis B viral DNA. Journal of Gastroenterology and Hepatology 14:5, 423-426
CrossRef470
HSIANG-HUNG SHIH, MEI-HWEI CHANG, HONG-YUAN HSU, PING-ING LEE, YEN-HSUAN NI, DING-SHINN CHEN. (1999) Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. The Pediatric Infectious Disease Journal 18:5, 427-432
CrossRef471
Muto, Yasutoshi, Moriwaki, Hisataka, , Saito, Akiko, . (1999) Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma. New England Journal of Medicine 340:13, 1046-1047
Full Text472
Daniel F Schafer, Michael F Sorrell. (1999) Hepatocellular carcinoma. The Lancet 353:9160, 1253-1257
CrossRef473
T. A. Ruff. (1999) Immunisation strategies for viral diseases in developing countries. Reviews in Medical Virology 9:2, 121-138
CrossRef474
Ince, Nedim, Wands, Jack R., . (1999) The Increasing Incidence of Hepatocellular Carcinoma. New England Journal of Medicine 340:10, 798-799
Full Text475
Li-Min Huang, Bor-Luen Chiang, Chin-Yun Lee, Ping-Ing Lee, Wei-Kuang Chi, Mei-Hwei Chang. (1999) Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 29:3, 954-959
CrossRef476
Joseph Torresi, Stephen A Locarnini. (1999) New therapeutic strategies in the treatment of hepatitis B virus infection. Expert Opinion on Investigational Drugs 8:3, 289-305
CrossRef477
J.-S. Wang, X. Shen, X. He, Y.-R. Zhu, B.-C. Zhang, J.-B. Wang, G.-S. Qian, S.-Y. Kuang, A. Zarba, P. A. Egner, L. P. Jacobson, A. Munoz, K. J. Helzlsouer, J. D. Groopman, T. W. Kensler. (1999) Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China. JNCI Journal of the National Cancer Institute 91:4, 347-354
CrossRef478
A.B McDermott, S.B.A Cohen, J.N Zuckerman, J.A Madrigal. (1999) Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 17:4, 330-339
CrossRef479
Adriana R. Marques, Stephen E. Straus. (1998) Advances in the treatment of chronic hepatitis B virus infection. Reviews in Medical Virology 8:4, 223-234
CrossRef480
Adrian M. Di Bisceglie, Robert L. CARITHERS, Gregory J. Gores. (1998) Hepatocellular carcinoma. Hepatology 28:4, 1161-1165
CrossRef481
Jean-Louis Excler. (1998) Potentials and limitations of protein vaccines in infants. Vaccine 16:14-15, 1439-1443
CrossRef482
Takashi Sugimura. (1998) Cancer prevention: past, present, future. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 402:1-2, 7-14
CrossRef483
MEI-HWEI CHANG. (1998) Chronic hepatitis virus infection in children. Journal of Gastroenterology and Hepatology 13:5, 541-548
CrossRef484
Drew M. Pardoll. (1998) Cancer vaccines. Nature Medicine 4:5s, 525-531
CrossRef485
Giuseppe Del Giudice, Mariagrazia Pizza, Rino Rappuoli. (1998) Molecular basis of vaccination. Molecular Aspects of Medicine 19:1, 1-70
CrossRef486
MA Buendia. (1998) Hepatitis B viruses and cancerogenesis. Biomedicine & Pharmacotherapy 52:1, 34-43
CrossRef487
Mark A. Kane. (1998) Situation internationale de la vaccination contre l'hépatite B en 1998. Sozial- und Präventivmedizin SPM 43:S1, S118-S120
CrossRef488
Daniel Desgrandchamps, Claire-Anne Siegrist. (1998) Les vaccins contre l'hépatite B. Sozial- und Präventivmedizin SPM 43:S1, S111-S114
CrossRef489
Daniel Desgrandchamps, Claire-Anne Siegrist. (1998) Die Impfung gegen Hepatitis B. Sozial- und Präventivmedizin SPM 43:S1, S37-S40
CrossRef490
Mark A. Kane. (1998) Zum weltweiten Stand der Hepatitis-B-Impfung 1998. Sozial- und Präventivmedizin SPM 43:S1, S44-S46
CrossRef491
Lee, William M., . (1997) Hepatitis B Virus Infection. New England Journal of Medicine 337:24, 1733-1745
Full Text492
Zuckerman, Arie J., . (1997) Prevention of Primary Liver Cancer by Immunization. New England Journal of Medicine 336:26, 1906-1907
Full Text
